# EDGAR Filing Document

**Accession Number:** 0001779128
**File Stem:** 0001628280-25-050870
**Filing Date:** 2025-11
**Character Count:** 255350
**Document Hash:** c72e2b6fdd06a82335fed49664f55ec4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-25-050870.hdr.sgml**: 20251110

**ACCESSION NUMBER**: 0001628280-25-050870

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 74

**CONFORMED PERIOD OF REPORT**: 20250930

**FILED AS OF DATE**: 20251110

**DATE AS OF CHANGE**: 20251110

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Strata Critical Medical, Inc.
- **CENTRAL INDEX KEY:** 0001779128
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-HEALTH SERVICES [8000]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 841890381
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39046
- **FILM NUMBER:** 251465171

**BUSINESS ADDRESS:**
- **STREET 1:** 31 HUDSON YARDS
- **STREET 2:** 14TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10001
- **BUSINESS PHONE:** 212-967-1009

**MAIL ADDRESS:**
- **STREET 1:** 31 HUDSON YARDS
- **STREET 2:** 14TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10001

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Blade Air Mobility, Inc.
- **DATE OF NAME CHANGE:** 20210507

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Experience Investment Corp.
- **DATE OF NAME CHANGE:** 20190606

?xml version='1.0' encoding='ASCII'? blde-20250930

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

499E

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**Form 10-Q**

**(Mark One)**

⌧ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended: September 30, 2025**

**OR**

□ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.**

**For the transition period from &nbsp;&nbsp;&nbsp;&nbsp;to** 

Commission File Number **001-39046**

**STRATA CRITICAL MEDICAL, INC.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **84-1890381** |
| (State or other jurisdiction<br>of incorporation or organization) | (I.R.S.Employer<br>Identification No.) |
| **31 Hudson Yards, 14th Floor**<br>**New York, NY** | **10001** |
| (Address of principal executive offices) | (Zip Code) |

---

---

| |
|:---|
| **(585) 301-1762** |
| (Registrant's telephone number, including area code) |

---

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on**<br>**which registered** |
| Common Stock, $0.0001 par value per share | SRTA | The Nasdaq Stock Market |
| Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share | SRTAW | The Nasdaq Stock Market |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧ No □

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S–T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ⌧ No □

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non–accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," " smaller reporting company," and "emerging growth company" in Rule 12b–2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | □ | Accelerated filer | ⌧ |
| Non-accelerated filer | □ | Smaller reporting company | ⌧ |
| Emerging growth company | □ | | |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b–2 of the Exchange Act). Yes □ No ⌧

As of November 3, 2025, there were 86,366,526 shares of the registrant's Common Stock, $0.0001 par value per share, issued and outstanding.

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**FORM 10-Q**

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
| | | Page |
| <u>[PART I. FINANCIAL INFORMATION](#i944bdb891dfe41689e63162637d304aa_19)</u> | <u>[PART I. FINANCIAL INFORMATION](#i944bdb891dfe41689e63162637d304aa_19)</u> | [3](#i944bdb891dfe41689e63162637d304aa_19) |
| &nbsp;&nbsp;<u>[Item 1.](#i944bdb891dfe41689e63162637d304aa_22)</u> | <u>[Financial statements](#i944bdb891dfe41689e63162637d304aa_22)</u> | [3](#i944bdb891dfe41689e63162637d304aa_22) |
|  | <u>[Unaudited Interim Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024](#i944bdb891dfe41689e63162637d304aa_28)</u> | [3](#i944bdb891dfe41689e63162637d304aa_28) |
|  | <u>[Unaudited Interim](#i944bdb891dfe41689e63162637d304aa_31)[Condensed](#i944bdb891dfe41689e63162637d304aa_28)[Consolidated Statements of Operations for the three and](#i944bdb891dfe41689e63162637d304aa_31)[nine](#i944bdb891dfe41689e63162637d304aa_31)[months ended](#i944bdb891dfe41689e63162637d304aa_31)[September](#i944bdb891dfe41689e63162637d304aa_31)[30, 2025 and 2024](#i944bdb891dfe41689e63162637d304aa_31)</u> | [4](#i944bdb891dfe41689e63162637d304aa_31) |
|  | <u>[Unaudited Interim](#i944bdb891dfe41689e63162637d304aa_34)[Condensed](#i944bdb891dfe41689e63162637d304aa_28)[Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended September 30, 2025 and 2024](#i944bdb891dfe41689e63162637d304aa_34)</u> | [5](#i944bdb891dfe41689e63162637d304aa_34) |
|  | <u>[Unaudited Interim](#i944bdb891dfe41689e63162637d304aa_37)[Condensed](#i944bdb891dfe41689e63162637d304aa_28)[Consolidated Statements of Stockholders' Equity for the three and](#i944bdb891dfe41689e63162637d304aa_37)[nine](#i944bdb891dfe41689e63162637d304aa_37)[months ended](#i944bdb891dfe41689e63162637d304aa_37)[September](#i944bdb891dfe41689e63162637d304aa_37)[30, 2025 and 2024](#i944bdb891dfe41689e63162637d304aa_37)</u> | [6](#i944bdb891dfe41689e63162637d304aa_40) |
|  | <u>[Unaudited Interim](#i944bdb891dfe41689e63162637d304aa_46)[Condensed](#i944bdb891dfe41689e63162637d304aa_28)[Consolidated Statements of Cash Flows for the](#i944bdb891dfe41689e63162637d304aa_46)[nine](#i944bdb891dfe41689e63162637d304aa_46)[months ended](#i944bdb891dfe41689e63162637d304aa_46)[September](#i944bdb891dfe41689e63162637d304aa_46)[30, 2025 and](#i944bdb891dfe41689e63162637d304aa_46)[2024](#i944bdb891dfe41689e63162637d304aa_31)</u> | [8](#i944bdb891dfe41689e63162637d304aa_46) |
|  | <u>[Notes to Unaudited Interim](#i944bdb891dfe41689e63162637d304aa_49)[Condensed](#i944bdb891dfe41689e63162637d304aa_28)[Consolidated Financial Statements](#i944bdb891dfe41689e63162637d304aa_49)</u> | [10](#i944bdb891dfe41689e63162637d304aa_49) |
| &nbsp;&nbsp;<u>[Item 2.](#i944bdb891dfe41689e63162637d304aa_160)</u> | <u>[Management's discussion and analysis of financial condition and results of operations](#i944bdb891dfe41689e63162637d304aa_160)</u> | [27](#i944bdb891dfe41689e63162637d304aa_160) |
| &nbsp;&nbsp;<u>[Item 3.](#i944bdb891dfe41689e63162637d304aa_226)</u> | <u>[Quantitative and qualitative disclosures about market risk](#i944bdb891dfe41689e63162637d304aa_226)</u> | [44](#i944bdb891dfe41689e63162637d304aa_226) |
| &nbsp;&nbsp;<u>[Item 4.](#i944bdb891dfe41689e63162637d304aa_229)</u> | <u>[Controls and procedures](#i944bdb891dfe41689e63162637d304aa_229)</u> | [44](#i944bdb891dfe41689e63162637d304aa_229) |
| <u>[PART II. OTHER INFORMATION](#i944bdb891dfe41689e63162637d304aa_232)</u> | <u>[PART II. OTHER INFORMATION](#i944bdb891dfe41689e63162637d304aa_232)</u> | [46](#i944bdb891dfe41689e63162637d304aa_232) |
| &nbsp;&nbsp;<u>[Item 1.](#i944bdb891dfe41689e63162637d304aa_277)</u> | <u>[Legal proceedings](#i944bdb891dfe41689e63162637d304aa_277)</u> | [46](#i944bdb891dfe41689e63162637d304aa_235) |
| &nbsp;&nbsp;<u>[Item 1A.](#i944bdb891dfe41689e63162637d304aa_238)</u> | <u>[Risk factors](#i944bdb891dfe41689e63162637d304aa_238)</u> | [46](#i944bdb891dfe41689e63162637d304aa_238) |
| &nbsp;&nbsp;<u>[Item 2.](#i944bdb891dfe41689e63162637d304aa_241)</u> | <u>[Unregistered sales of equity securities, use of proceeds and Issuer purchases of equity securities](#i944bdb891dfe41689e63162637d304aa_241)</u> | [47](#i944bdb891dfe41689e63162637d304aa_241) |
| &nbsp;&nbsp;<u>[Item 3.](#i944bdb891dfe41689e63162637d304aa_244)</u> | <u>[Defaults upon senior securities](#i944bdb891dfe41689e63162637d304aa_244)</u> | [47](#i944bdb891dfe41689e63162637d304aa_244) |
| &nbsp;&nbsp;<u>[Item 4.](#i944bdb891dfe41689e63162637d304aa_247)</u> | <u>[Mine safety disclosures](#i944bdb891dfe41689e63162637d304aa_247)</u> | [47](#i944bdb891dfe41689e63162637d304aa_247) |
| &nbsp;&nbsp;<u>[Item 5.](#i944bdb891dfe41689e63162637d304aa_250)</u> | <u>[Other information](#i944bdb891dfe41689e63162637d304aa_250)</u> | [47](#i944bdb891dfe41689e63162637d304aa_250) |
| &nbsp;&nbsp;<u>[Item 6.](#i944bdb891dfe41689e63162637d304aa_253)</u> | <u>[Exhibits](#i944bdb891dfe41689e63162637d304aa_253)</u> | [48](#i944bdb891dfe41689e63162637d304aa_253) |
| <u>[SIGNATURES](#i944bdb891dfe41689e63162637d304aa_256)</u> | <u>[SIGNATURES](#i944bdb891dfe41689e63162637d304aa_256)</u> | [50](#i944bdb891dfe41689e63162637d304aa_256) |

---

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

**PART I. FINANCIAL INFORMATION**

**Item 1. Financial Statements**

**STRATA CRITICAL MEDICAL, INC.** 

**Unaudited Interim Condensed Consolidated Balance Sheets**

*(in thousands, except share and per share data)*

---

| | | |
|:---|:---|:---|
| | **September 30,<br>2025** | **December 31,<br>2024** |
| **Assets** | | |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $22753 | $16072 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restricted cash | 263 | 263 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | 37538 | 19822 |
| &nbsp;&nbsp;&nbsp;&nbsp;Short-term investments | 53165 | 108757 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 8763 | 4676 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current assets of discontinued operations |  | 11152 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 122482 | 160742 |
| Non-current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Property and equipment, net | 38561 | 28465 |
| &nbsp;&nbsp;&nbsp;&nbsp;Intangible assets, net | 49754 | 7964 |
| &nbsp;&nbsp;&nbsp;&nbsp;Goodwill | 84607 | 15540 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating right-of-use asset | 3274 | 2831 |
| &nbsp;&nbsp;&nbsp;&nbsp;Contingent consideration | 27825 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other non-current assets | 8575 | 118 |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-current assets of discontinued operations |  | 41015 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $335078 | $256675 |
| **Liabilities and Stockholders' Equity** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;Accounts payable and accrued expenses | $27220 | $9220 |
| &nbsp;&nbsp;Operating lease liability, current | 654 | 682 |
| &nbsp;&nbsp;Current liabilities of discontinued operations |  | 12824 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 27874 | 22726 |
| Non-current liabilities: |  |  |
| &nbsp;&nbsp;Warrant liability | 2946 | 5808 |
| &nbsp;&nbsp;Operating lease liability, long-term | 2817 | 2336 |
| &nbsp;&nbsp;Deferred tax liability | 181 |  |
| &nbsp;&nbsp;Other non-current liabilities | 18260 |  |
| &nbsp;&nbsp;Non-current liabilities of discontinued operations |  | 3867 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 52078 | 34737 |
| Commitments and Contingencies (Note 9) |  |  |
| **Stockholders' Equity** |  |  |
| &nbsp;&nbsp;Preferred stock, $0.0001 par value, 2,000,000 shares authorized; no shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively |  |  |
| Common stock, $0.0001 par value; 400,000,000 authorized; 86,050,917 and 79,419,028 shares issued at September 30, 2025 and December 31, 2024, respectively | 7 | 7 |
| &nbsp;&nbsp;Additional paid in capital | 419711 | 407076 |
| &nbsp;&nbsp;Accumulated other comprehensive income (loss) |  | 1753 |
| &nbsp;&nbsp;Accumulated deficit | (136718) | (186898) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 283000 | 221938 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Liabilities and Stockholders' Equity | $335078 | $256675 |

---

 *See Notes to Unaudited Interim Condensed Consolidated Financial Statements.*

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Unaudited Interim Condensed Consolidated Statements of Operations**

*(in thousands, except share and per share data)*

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Revenue | $49298 | $36062 | $130354 | $110429 |
| Operating expenses |  |  |  |  |
| &nbsp;&nbsp;Cost of revenue | 37684 | 28554 | 100898 | 85854 |
| &nbsp;&nbsp;Software development | 453 | 417 | 1354 | 1031 |
| &nbsp;&nbsp;General and administrative | 16301 | 13869 | 42954 | 39140 |
| &nbsp;&nbsp;Selling and marketing | 482 | 314 | 1096 | 1025 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 54920 | 43154 | 146302 | 127050 |
| Operating loss from continuing operations | (5622) | (7092) | (15948) | (16621) |
| Other non-operating income (loss) |  |  |  |  |
| &nbsp;&nbsp;Interest income | 1127 | 1764 | 3603 | 5624 |
| &nbsp;&nbsp;Change in fair value of warrant liabilities | 33 | (299) | 2862 | 2266 |
| &nbsp;&nbsp;Realized loss from sales of short-term investments | (5195) |  | (5195) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total other non-operating income (loss) | (4035) | 1465 | 1270 | 7890 |
| Loss from continuing operations before income taxes | (9657) | (5627) | (14678) | (8731) |
| &nbsp;&nbsp;Income tax expense (benefit) from continuing operations |  |  |  |  |
| Net loss from continuing operations | (9657) | (5627) | (14678) | (8731) |
| &nbsp;&nbsp;Net income (loss) from discontinued operations | 67073 | 3673 | 64858 | (8783) |
| Net income (loss) | $57416 | $(1954) | $50180 | $(17514) |
| Basic and diluted earnings (loss) per share |  |  |  |  |
| &nbsp;&nbsp;Continuing operations | $(0.12) | $(0.07) | $(0.18) | $(0.11) |
| &nbsp;&nbsp;Discontinued operations | $0.81 | $0.05 | $0.80 | $(0.11) |
| Total basic and diluted earnings (loss) per share | $0.70 | $(0.03) | $0.62 | $(0.23) |
| Weighted-average number of shares outstanding: |  |  |  |  |
| &nbsp;&nbsp;Basic | 82454657 | 78044254 | 81223912 | 77151361 |
| &nbsp;&nbsp;Diluted | 82454657 | 78044254 | 81223912 | 77151361 |

---

 *See Notes to Unaudited Interim Condensed Consolidated Financial Statements.*

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Unaudited Interim Condensed Consolidated Statements of Comprehensive Income (Loss)**

*(in thousands)*

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Net income (loss) | $57416 | $(1954) | $50180 | $(17514) |
| Other comprehensive income (loss): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Foreign currency translation adjustments (Note 4) | (5968) | 1396 | (1753) | 209 |
| Other comprehensive income (loss) | (5968) | 1396 | (1753) | 209 |
| Comprehensive income (loss) | $51448 | $(558) | $48427 | $(17305) |

---

*See Notes to Unaudited Interim Condensed Consolidated Financial Statements.*

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Unaudited Interim Condensed Consolidated Statements of Stockholders' Equity** 

*(in thousands, except share data)*

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Common Stock** | **Common Stock** | **Additional Paid-In Capital** | **Accumulated Other Comprehensive Income** | **Accumulated<br>Deficit** | **Total<br>Stockholders'<br>Equity** |
| | **Shares** | **Amount** | **Additional Paid-In Capital** | **Accumulated Other Comprehensive Income** | **Accumulated<br>Deficit** | **Total<br>Stockholders'<br>Equity** |
| **Balance as of July 1, 2025** | **81695605** | $**7** | $**411259** | $**5968** | $**(194134)** | $**223100** |
| Issuance of common stock upon exercise of stock options | 365652 |  | 65 |  |  | 65 |
| Issuance of common stock upon settlement of restricted stock units | 1017440 |  |  |  |  |  |
| Stock-based compensation - restricted stock |  |  | 1825 |  |  | 1825 |
| Shares withheld related to net share settlement | (462389) |  | (1852) |  |  | (1852) |
| Issuance of common stock in acquisition | 3434609 |  | 8414 |  |  | 8414 |
| Other comprehensive loss |  |  |  | (5968) |  | (5968) |
| Net income |  |  |  |  | 57416 | 57416 |
| **Balances as of September 30, 2025** | **86050917** | $**7** | $**419711** | $**—** | $**(136718)** | $**283000** |
| **Balance as of July 1, 2024** | **77934085** | $**7** | $**401753** | $**2777** | $**(175151)** | $**229386** |
| Issuance of common stock upon exercise of stock options | 59000 |  | 11 |  |  | 11 |
| Issuance of common stock upon settlement of restricted stock units | 581305 |  |  |  |  |  |
| Stock-based compensation - restricted stock |  |  | 5402 |  |  | 5402 |
| Shares withheld related to net share settlement | (260367) |  | (742) |  |  | (742) |
| Repurchase and retirement of common stock |  |  |  |  |  |  |
| Other comprehensive income |  |  |  | 1396 |  | 1396 |
| Net loss |  |  |  |  | (1954) | (1954) |
| **Balances as of September 30, 2024** | **78314023** | $**7** | $**406424** | $**4173** | $**(177105)** | $**233499** |

---

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Common Stock** | **Common Stock** | **Additional Paid-In Capital** | **Accumulated Other Comprehensive Income** | **Accumulated<br>Deficit** | **Total<br>Stockholders'<br>Equity** |
| | **Shares** | **Amount** | **Additional Paid-In Capital** | **Accumulated Other Comprehensive Income** | **Accumulated<br>Deficit** | **Total<br>Stockholders'<br>Equity** |
| **Balance as of January 1, 2025** | **79419028** | $**7** | $**407076** | $**1753** | $**(186898)** | $**221938** |
| Issuance of common stock upon exercise of stock options | 1977499 |  | 139 |  |  | 139 |
| Issuance of common stock upon settlement of restricted stock units | 3468117 |  |  |  |  |  |
| Stock-based compensation - restricted stock |  |  | 11391 |  |  | 11391 |
| Shares withheld related to net share settlement | (2248336) |  | (7309) |  |  | (7309) |
| Issuance of common stock in acquisition | 3434609 |  | 8414 |  |  | 8414 |
| Other comprehensive loss |  |  |  | (1753) |  | (1753) |
| Net income |  |  |  |  | 50180 | 50180 |
| **Balances as of September 30, 2025** | **86050917** | $**7** | $**419711** | $**—** | $**(136718)** | $**283000** |
| **Balance as of January 1, 2024** | **75131425** | $**7** | $**390083** | $**3964** | $**(159754)** | $**234300** |
| Issuance of common stock upon exercise of stock options | 690463 |  | 124 |  |  | 124 |
| Issuance of common stock upon settlement of restricted stock units | 2167937 |  |  |  |  |  |
| Stock-based compensation - restricted stock |  |  | 15367 |  |  | 15367 |
| Shares withheld related to net share settlement | (604698) |  | (1765) |  |  | (1765) |
| Issuance of common stock for settlement of contingent consideration compensation (earn-out) | 1008998 |  | 3022 |  |  | 3022 |
| Repurchase and retirement of common stock | (80102) |  | (407) |  | 163 | (244) |
| Other comprehensive income |  |  |  | 209 |  | 209 |
| Net loss |  |  |  |  | (17514) | (17514) |
| **Balances as of September 30, 2024** | **78314023** | $**7** | $**406424** | $**4173** | $**(177105)** | $**233499** |

---

*See Notes to Unaudited Interim Condensed Consolidated Financial Statements*

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Unaudited Interim Condensed Consolidated Statements of Cash Flows**

*(in thousands)*

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** |
| **Cash Flows From Operating Activities:** |  |  |
| Net income / (loss) | $50180 | $(17514) |
| &nbsp;&nbsp;Adjustments to reconcile net loss to net cash and restricted cash used in operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on sale of business | (60435) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 5177 | 4432 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 11246 | 15367 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of warrant liabilities | (2862) | (2266) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Excess of lease liability over operating right-of-use assets |  | (123) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transaction costs paid related to sale of business | (5964) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Acquisition consideration allocated to seller transaction expenses | (44339) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment of intangible assets |  | 5759 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Realized loss from sales of short-term investments | 5195 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Realized foreign exchange gain | (798) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accretion of interest income on held-to-maturity securities | (1732) | (3120) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred tax expense (benefit) | 558 | (150) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | 388 | 87 |
| &nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 776 | 8312 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | (8551) | (3611) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other non-current assets | 666 | 492 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating right-of-use assets/lease liabilities | (90) | 81 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses | 8395 | (8336) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other current liabilities | 1583 | (177) |
| **Net cash used in operating activities** | (40607) | (767) |
| **Cash Flows From Investing Activities:** |  |  |
| &nbsp;&nbsp;Acquisitions, net of cash acquired | (65174) | (2230) |
| &nbsp;&nbsp;Cash transfer from sale of business | (1241) |  |
| &nbsp;&nbsp;Capitalized software development costs | (1258) | (1660) |
| &nbsp;&nbsp;Purchase of property and equipment, net of proceeds from disposal | (7747) | (26286) |
| &nbsp;&nbsp;Purchase of held-to-maturity investments | (146258) | (142766) |
| &nbsp;&nbsp;Proceeds from maturities of held-to-maturity investments | 203000 | 167950 |
| &nbsp;&nbsp;Proceeds from sale of short-term investments | 70163 |  |
| **Net cash provided by / (used in) investing activities** | 51485 | (4992) |
| **Cash Flows From Financing Activities:** |  |  |
| &nbsp;&nbsp;Proceeds from the exercise of common stock options | 139 | 124 |
| &nbsp;&nbsp;Taxes paid related to net share settlement of equity awards | (7309) | (1765) |
| &nbsp;&nbsp;Repurchase and retirement of common stock |  | (244) |
| **Net cash used in financing activities** | (7170) | (1885) |
| Effect of foreign exchange rate changes on cash balances | (339) | 29 |
| **Net increase (decrease) in cash and cash equivalents and restricted cash** | 3369 | (7615) |
| **Cash and cash equivalents and restricted cash - beginning** | 19647 | 29021 |
| **Cash and cash equivalents and restricted cash - ending** | $23016 | $21406 |
| **Reconciliation to unaudited interim condensed consolidated balance sheets** |  |  |
| Cash and cash equivalents | $22753 | $20028 |
| Restricted cash | 263 | 1378 |
| Total cash and cash equivalents and restricted cash | $23016 | $21406 |
| **Supplemental cash flow information** |  |  |
| &nbsp;&nbsp;Cash paid for: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Income Taxes paid | $23 | $— |
| &nbsp;&nbsp;Non-cash financing and investing activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock received for sale of business | $75357 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Contingent consideration and indemnity holdback receivable from sale of business in contingent consideration and other non-current assets, respectively | 36233 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;New leases under ASC 842 entered into during the period | 1597 | $8545 |

---

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;Contingent consideration in accounts payable and accrued expenses and other non-current liabilities | 9215 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock issued for acquisition | 8414 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of property and equipment and capitalized software in accounts payable and accrued expenses | 518 | 3479 |
| &nbsp;&nbsp;&nbsp;&nbsp;Derecognition of ROU assets and lease liability |  | (6367) |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock issued for settlement of earn-out previously in accounts payable and accrued expenses |  | 3022 |

---

*See Notes to Unaudited Interim Condensed Consolidated Financial Statements.*

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Notes to Unaudited Interim Condensed Consolidated Financial Statements**

*(amounts in thousands, except share and per share data)*

**Note 1 – Description of Business and Summary of Significant Accounting Policies**

***Description of Business***

Strata Critical Medical, Inc. ("Strata" or the "Company") is a time-critical logistics and medical services provider to the United States healthcare industry. The Company operates one of the nation's largest air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated "one call" solution for donor organ recovery. Strata's core services include air and ground logistics, surgical organ recovery, organ placement and normothermic regional perfusion for the transplant industry, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers, offered under the Trinity Medical Solutions ("Trinity") and Keystone Perfusion brands.

Strata's mission is to increase the number of organs that are successfully transplanted while leveraging the Company's expertise and resources to provide other medical and logistics services to a broader customer base. Strata's goals are closely aligned with those of all participants in the transplant ecosystem, including transplant centers, regulators, Organ Procurement Organizations ("OPOs") and other service providers.

On August 29, 2025, the Company completed the sale of its Passenger business to Joby Aero, Inc. ("Joby Buyer"), a wholly owned subsidiary of Joby Aviation, Inc. ("Joby Aviation"). The sale followed the separation of the Passenger business, which provided air and ground transportation services for passengers on third-party aircraft, from the Company's remaining medical operations.

On September 16, 2025, the Company completed the acquisition of Keystone Perfusion Services, LLC, a Pennsylvania limited liability company ("Keystone"), an organ recovery and normothermic regional perfusion service provider to the transplant industry, pursuant to a Purchase and Sale Agreement, dated September 16, 2025 (the "Keystone Purchase Agreement").

***Basis of Presentation and Principles of Consolidation***

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") for interim financial information and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Management's opinion is that all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of financial position, results of operations and cash flows at the dates and for the periods presented have been included. Operating results for the three and nine months ended September 30, 2025 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2025. These financial statements should be read in conjunction with the Company's consolidated financial statements and accompanying Notes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2024.

As discussed in Note 3, on August 29, 2025, the Company completed the previously announced sale of its Passenger business to Joby Buyer pursuant to the Joby Purchase Agreement (as defined below), dated August 1, 2025.

The results of the Passenger business are presented as discontinued operations in the accompanying unaudited interim condensed consolidated statement of operations for all periods presented. The assets and liabilities of the Passenger business have been reflected as assets and liabilities of discontinued operations in the accompanying unaudited interim condensed consolidated balance sheets for all prior periods presented. Unless otherwise noted, all amounts and disclosures included in these notes to the unaudited interim condensed consolidated financial statements reflect only our continuing operations. Refer to Note 3 for additional details on discontinued operations. Certain prior year amounts have been reclassified to conform to the current year presentation.

***Short-Term Investments***

*Held-to-Maturity Securities*

The Company's investments in held-to-maturity securities consist of investment grade U.S. Treasury obligations with maturity dates of less than 365 days. The Company has the ability and intention to hold these securities until maturity. Accordingly, these securities are recorded in the Company's unaudited interim condensed consolidated balance sheet at

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Notes to Unaudited Interim Condensed Consolidated Financial Statements**

*(amounts in thousands, except share and per share data)*

amortized cost and interest is recorded within interest income on the Company's unaudited interim condensed consolidated statement of operations. The held-to-maturity securities balance and fair market value at September 30, 2025 and December 31, 2024 were $53,165 and $53,164, and $108,757 and $108,832, respectively. The held-to-maturity securities gross unrealized holding loss as of September 30, 2025 and 2024 were $1 and $199, respectively. The fair value hierarchy of the valuation inputs the Company utilized to determine such fair market value is Level 2.

***Concentrations***

Financial instruments which potentially subject the Company to concentrations of credit risk consists principally of cash amounts on deposit with financial institutions. At times, the Company's cash in banks is in excess of the Federal Deposit Insurance corporation ("FDIC") insurance limit. The Company has not experienced any loss as a result of these deposits.

*Major Customers*

One customer accounted for 13% of the Company's revenue for the three months ended September 30, 2025. One customer accounted for 16% of the Company's revenue for the three months ended September 30, 2024.

One customer accounted for 13% of the Company's revenue for the nine months ended September 30, 2025. One customer accounted for 17% of the Company's revenue for the nine months ended September 30, 2024.

No single customer accounted for 10% or more of the Company's outstanding accounts receivable as of September 30, 2025. One customer accounted for 11% of the Company's outstanding accounts receivable as of December 31, 2024.

*Major Vendors*

Two vendors accounted for 17% and 10%, respectively, of the Company's purchases from operating vendors for the three months ended September 30, 2025. Three vendors accounted for 16%, 13% and 10%, respectively, of the Company's purchases from operating vendors for the three months ended September 30, 2024.

Two vendors accounted for 18% and 10%, respectively, of the Company's purchases from operating vendors for the nine months ended September 30, 2025. Three vendors accounted for 18%, 12% and 10%, respectively, of the Company's purchases from operating vendors for the nine months ended September 30, 2024.

One vendor accounted for 22% of the Company's outstanding accounts payable as of September 30, 2025. Two vendors accounted for 24% and 21%, respectively, of the Company's outstanding accounts payable as of December 31, 2024.

***Property and Equipment, Net***

---

| | | | |
|:---|:---|:---|:---|
| | **Useful Life** <br>**(in years)** | **September 30,<br>2025** | **December 31,<br>2024** |
| Aircraft, engines and related rotable parts (1) | 2 - 20 | $33894 | $27206 |
| Vehicles (1) | 5 | 3380 | 2648 |
| Leasehold improvements (2) | Shorter of useful life or life of lease | 835 | 734 |
| Furniture and fixtures (2) | 5 | 405 | 401 |
| Technology equipment (2) | 3 | 66 | 50 |
| Medical and other machinery equipment (1) | 5 | 4924 |  |
| Total property and equipment, gross |  | 43504 | 31039 |
| Less: Accumulated depreciation |  | (4943) | (2574) |
| Total property and equipment, net |  | $38561 | $28465 |

---

(1) Depreciation expense is included within cost of revenue.

(2) Depreciation expense is included within general and administrative expenses.

For the three months ended September 30, 2025 and 2024, the Company recorded depreciation expense for property and equipment of $1,081 and $558, respectively. For the nine months ended September 30, 2025 and 2024, the Company

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Notes to Unaudited Interim Condensed Consolidated Financial Statements**

*(amounts in thousands, except share and per share data)*

recorded depreciation expense for property and equipment of $2,764 and $1,224, respectively. For the nine months ended September 30, 2025, the Company disposed of $432 in property and equipment and likewise wrote off previously recognized accumulated depreciation of $350. For the nine months ended September 30, 2024, disposals of certain property and equipment were immaterial.

***Business Combinations and Contingent Consideration***

Business combinations are accounted for using the acquisition method. The Company allocates the fair value of the purchase price of an acquisition to the assets acquired and liabilities assumed, based on their estimated fair values as of the date of acquisition. The excess of the fair value of the purchase price over the fair values of these net tangible and intangible assets acquired is recorded as goodwill. Fair value of the acquired intangible assets was determined using an income approach, specifically the multi-period excess earnings method or relief-from-royalty method, depending on the nature of the respective assets. Management's estimates of fair value are based upon assumptions believed to be reasonable, but the estimates and assumptions are inherently uncertain and subject to refinement. The significant judgments and assumptions used in valuing the developed technology and trademark include revenue growth rates, EBITDA margin, tax rate, the discount rate, and the royalty rate. For customer relationships, the significant judgments and assumptions include revenue growth rates, customer attrition rate, EBITDA margin, tax rate, contributory asset valuations, and the discount rate. These estimates are inherently uncertain and, therefore, actual results may differ from the estimates made. As a result, during the measurement period of up to one year from the acquisition date, the Company may make adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the measurement period's conclusion or final determination of the fair value of the purchase price of an acquisition, whichever comes first, any subsequent adjustments are recorded to our consolidated statements of operations in the period they are identified. Acquisition-related expenses are recognized separately from the business combination and expensed as incurred.

Certain business combinations include contingent consideration arrangements, which are generally based on achievement of future financial performance or future events. If it is determined the contingent consideration arrangement is not compensatory, the Company estimates fair value of contingent consideration payments as part of the initial purchase price and records the estimated fair value of contingent consideration as a liability in the consolidated balance sheet. The Company reviews and assesses the estimated fair value of contingent consideration each reporting period, and the updated fair value could differ materially from the initial estimates. Changes in the estimated fair value of the contingent consideration are recognized in earnings in the consolidated statements of operations.

***Use of Estimates***

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates on historical experience, current business factors, and various other assumptions that the Company believes are necessary to consider to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses, and the disclosure of contingent assets and liabilities. The Company is subject to uncertainties such as the impact of future events, economic and political factors, and changes in the Company's business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in the preparation of the Company's financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as the Company's operating environment evolves.

Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in reported results of operations; if material, the effects of changes in estimates are disclosed in the notes to the financial statements. Significant estimates and assumptions by management include, but are not limited to, the fair value of contingent consideration, intangible assets, goodwill and stock-based payment liability-classified awards.

***Recently Issued Accounting Pronouncements - Not Adopted***

In October 2023, the FASB issued ASU 2023-06, *Disclosure Improvements.* The new guidance clarifies or improves disclosure and presentation requirements on a variety of topics in the codification. The amendments in the update are intended to align the requirements in the FASB ASC with the SEC's regulations. The amendments are effective prospectively on the date each individual amendment is effectively removed from Regulation S-X or Regulation S-K, or if the SEC has not removed the requirements by June 30, 2027, this amendment will be removed from the Codification and

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Notes to Unaudited Interim Condensed Consolidated Financial Statements**

*(amounts in thousands, except share and per share data)*

will not become effective for any entity. The Company is in the process of evaluating the impact the adoption of this ASU will have on the financial statements and related disclosures.

In December 2023, the FASB issued ASU 2023-09, *Improvements to Income Tax Disclosures (Topic 740)*. The ASU requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective for annual periods beginning after December 15, 2024 on a prospective basis. Early adoption is also permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is in the process of evaluating the impact the adoption of this ASU will have on the financial statements and related disclosures.

In November 2024, the FASB issued ASU 2024-03, *Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses.* The ASU requires additional disclosure of the nature of expenses included in the income statement as well as disclosures about specific types of expenses included in the expense captions presented in the income statement as well as disclosures about selling expenses. The ASU is effective for annual periods beginning after December 15, 2026. Early adoption is permitted. The Company is in the process of evaluating the impact the adoption of this ASU will have on the financial statements and related disclosures.

In July 2025, the FASB issued ASU 2025-05, *Financial Instruments — Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets.* The ASU amends guidance for measuring credit losses on current accounts receivable and current contract assets arising from transactions accounted for under ASC 606, Revenue from Contracts with Customers. The ASU is effective for annual periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods. Early adoption is also permitted for annual or interim financial statements that have not yet been issued or made available for issuance. The Company is in the process of evaluating the impact the adoption of this ASU will have on the financial statements and related disclosures.

In September 2025, the FASB issued ASU 2025-06, *Intangibles — Goodwill and Other — Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software*. The ASU clarifies and modernizes the accounting for costs related to internal-use software. The ASU is effective for annual periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods. Early adoption is also permitted for annual or interim financial statements that have not yet been issued or made available for issuance. The Company is in the process of evaluating the impact the adoption of this ASU will have on the financial statements and related disclosures.

Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force) and the SEC have not had, or are not anticipated to have, a significant effect on the Company's unaudited interim condensed consolidated financial statements, both present and future.

**Note 2 – Acquisitions**

***Acquisition of Keystone Perfusion Services, LLC.***

As discussed in Note 1**,** on September 16, 2025, the Company acquired 100% of the equity interests in Keystone, an organ recovery and normothermic regional perfusion service provider to the transplant industry, for the following upfront payments: cash $109,963 (comprised of $65,624 paid directly to the seller and $44,339 directed by the seller to other parties on the close date) and 3,434,609 shares (valued at $16,828 based on the closing date share price) of which 1,717,303 shares are held in escrow.

The purchase price is subject to final adjustment, upward or downward by up to $12,400, based on Keystone's actual 2025 adjusted EBITDA performance, with the adjustment to be determined by March 2026. In addition, potential earn-out payments of up to $23,000 may be made contingent upon Keystone's achievement of gross profit targets (as defined in the Keystone Purchase Agreement) for each of the years 2026 to 2028. Acquisition-related costs totaling $1,157 were expensed as incurred and are included in general and administrative expenses in the unaudited interim condensed consolidated statements of operations for the nine months ended September 30, 2025. Keystone is a wholly-owned

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Notes to Unaudited Interim Condensed Consolidated Financial Statements**

*(amounts in thousands, except share and per share data)*

subsidiary of the Company and the results of Keystone for the period from September 16, 2025 ("acquisition date") to September 30, 2025 are included in the unaudited interim condensed consolidated financial statements.

*Escrow Consideration*

$315 in cash and 1,717,303 shares (valued at $8,414 based on the closing date share price) of the Company's common stock are held in escrow as of the acquisition date for a period of 12 months. The Company determined that there are two components to the escrow consideration related to purchase consideration and contingent consideration. The common stock balance in escrow is designated for indemnification obligations, net working capital adjustments, and a portion of the purchase price adjustment following the determination of Keystone's 2025 adjusted EBITDA.

The Company accounted for the $8,414 value of shares in escrow as a liability on the unaudited interim condensed consolidated balance sheet. As of the acquisition date, the contingent equity consideration was estimated to be $8,414. The shares in escrow are classified as a liability rather than equity because the Company remains the beneficial owner of the shares while they are held in escrow, with voting rights and dividends retained by the Company, and their release depends on Keystone's future financial performance. The contingent equity consideration will be subsequently remeasured at each reporting date with changes in fair value recognized as a component of operating expense on the Company's consolidated statements of operations, until settlement in the second quarter of 2026, when determination of the 2025 EBITDA earn-out will finalize the contingency and end remeasurement.

*Contingent Considerations*

The Company is required to calculate fair value of contingent considerations on each balance sheet date which will be subsequently remeasured at each reporting date with changes in fair value recognized as a component of operating expense on the Company's consolidated statements of operations. Refer to Note 11 for additional information.

As of the acquisition date, the net contingent considerations was estimated to be a liability of $800 comprised of the following: the fair value of the potential purchase adjustment (an upward or downward adjustment by up to $12,400 to be settled by March 2026) was determined to be a $2,800 receivable, and the fair value of the potential earn-out payments of up to $23,000, contingent upon Keystone's achievement of gross profit targets in each of the years 2026 to 2028, was determined to be a $3,600 payable.

*Net Assets Acquired*

The assets acquired and liabilities assumed have been included in the unaudited interim condensed consolidated financial statements as of the acquisition date. Total assets acquired included a preliminary estimate of identifiable intangible assets of $42,600. At the time of acquisition, the Company recognized an asset for a preliminary estimate of goodwill, determined as the excess of the purchase price over the net fair value of the assets acquired and liabilities assumed that amounted to $69,067. Goodwill primarily reflects expected revenue and cost synergies from expansion into additional medical services, the strategic benefit of offering a comprehensive suite of transplant solutions (surgical recovery, normothermic regional perfusion, air and ground logistics, and organ placement), and the value of the assembled workforce and their industry expertise. The acquisition is considered a taxable business combination, and goodwill is deductible for tax purposes.

The purchase price allocation is preliminary and, as additional information becomes available, the Company may further revise the preliminary purchase price allocation during the remainder of the measurement period, which will not exceed 12 months from the acquisition date. Measurement period adjustments will be recognized in the reporting period in which the adjustment amounts are determined. The purchase price was allocated on a preliminary basis as follows:

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Notes to Unaudited Interim Condensed Consolidated Financial Statements**

*(amounts in thousands, except share and per share data)*

---

| | |
|:---|:---|
| Cash paid directly to seller | $65624 |
| Equity consideration | 8414 |
| Equity consideration in escrow | 8414 |
| Contingent considerations (1) | 800 |
| &nbsp;&nbsp;Total purchase consideration | $83252 |
| Assets acquired: |  |
| Cash | $450 |
| Accounts receivable | 11674 |
| Prepaid expenses and other current assets | 3420 |
| Property and equipment, net | 4996 |
| Identifiable intangible assets | 42600 |
| Other non-current assets | 10 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total identifiable assets acquired | 63150 |
| Liabilities assumed: |  |
| Acquiree liabilities settled by the buyer in cash on close date (2) | 44339 |
| Accounts payable and accrued expenses | 3964 |
| Deferred revenue | 662 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total liabilities assumed | 48965 |
| Net assets acquired | 14185 |
| Goodwill | 69067 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total consideration | $83252 |

---

(1) Comprised of the 2026 to 2028 gross profit earn-out payments of $3,600 net of purchase price final adjustment of $2,800 following the determination of Keystone's final 2025 adjusted EBITDA.

(2) Seller transaction expenses paid in cash by the Company at closing to third parties at the direction of the seller.

A preliminary assessment of the fair value of identified intangible assets and their respective lives as of the acquisition date are as follows:

---

| | | |
|:---|:---|:---|
| | **Estimated Useful Life** | **Fair Value** |
| Customer list | 10 | $32800 |
| Trademarks | 10 | 8800 |
| Developed technology | 3 | 1000 |
| &nbsp;&nbsp;Total identifiable intangible assets |  | $42600 |

---

Identified intangible assets in the table above are amortized on a straight-line basis over the estimated useful lives. The Company believes that the straight-line method of amortization is the most appropriate methodology as it is supported by the pattern in which the economic benefits of the intangible assets are consumed.

The fair value of the customer relationships was determined using the multi-period excess earnings method ("MPEEM"). MPEEM is an income approach methodology which measures economic benefits by calculating the cash flow attributable to an asset after deducting appropriate returns for contributory assets used by the business in generating the asset's revenue and earnings. The fair value of the trademark and developed technology were determined using the relief-from-royalty approach. This approach is commonly used for measuring the fair value of intangible assets that are often the subject of licensing, such as trade names, patents, and proprietary technologies. The fundamental concept underlying this method is that in lieu of ownership, the acquirer can obtain comparable rights to use the subject asset via a license from a hypothetical third-party owner. The asset's fair value is the present value of license fees avoided by owning it (i.e., the royalty savings).

***Unaudited Pro Forma Information***

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Notes to Unaudited Interim Condensed Consolidated Financial Statements**

*(amounts in thousands, except share and per share data)*

The following unaudited pro forma financial information presents what our results would have been had Keystone been acquired on January 1, 2024. The unaudited pro forma information presented below is for informational purposes only and is not necessarily indicative of our unaudited interim condensed consolidated results of operations of the consolidated business had the Keystone acquisition actually occurred on January 1, 2024 or of the results of our future operations of the consolidated business.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| **Reported revenue** | $49298 | $36062 | $130354 | $110429 |
| Impact of Keystone | 16969 | 11757 | 49096 | 30234 |
| Pro forma revenue | $66267 | $47819 | $179450 | $140663 |
| **Reported loss from continuing operations before income taxes** | $(9657) | $(5627) | $(14678) | $(8731) |
| Impact of Keystone | 2090 | 1220 | 7261 | 3262 |
| Pro forma loss from continuing operations before income taxes | $(7567) | $(4407) | $(7417) | $(5469) |

---

**Note 3 – Discontinued Operations**

***Passenger Business Divestiture***

On August 29, 2025, the Company completed the sale of its Passenger business to Joby Buyer pursuant to that certain Equity Purchase Agreement, dated as of August 1, 2025 (the "Joby Purchase Agreement"), among the Company, Strata Critical, Inc. (f/k/a Trinity Medical Intermediate II, Inc.), a wholly owned subsidiary of the Company, Blade Urban Air Mobility, LLC (f/k/a Blade Urban Air Mobility, Inc.), Joby Aviation and Joby Buyer, a wholly owned subsidiary of Joby Aviation. The transaction followed restructuring activities to separate the Passenger business from the Company's remaining operations. The majority of the Passenger business sold was previously reported as the Company's Passenger segment under ASC 280, *Segment Reporting*, and consisted of offering, marketing and arranging air transportation services for passengers on aircraft operated by third parties as well as related ground transportation services.

At closing, the Company received consideration valued at approximately $75,357 (based on Joby Aviation's closing stock price of $14.15 on August 29, 2025), after giving effect to pre-closing adjustments. The consideration consisted of 5,325,585 shares of Joby Aviation's common stock, par value $0.0001 per share (the "Buyer Shares"). The Company subsequently sold the Buyer Shares for net proceeds of $70,163. The Company may also receive up to an additional $35,000, payable in cash or Buyer Shares at Joby Buyer's election, upon the achievement of certain financial performance and employee retention targets within 12 and 18 months, respectively, following the closing, as well as the release of up to $10,000 in indemnity holdbacks. The estimated fair value of the contingent consideration for retention and earn-out and indemnity holdbacks is $27,825 and $8,400, respectively. The fair value of the contingent consideration earn-out was determined using a probability-weighted discounted cash flow analysis based on internal projections of the buyer's expected future sales.

In connection with the sale, the Company reclassified $2,818 of cumulative foreign currency translation gain from accumulated other comprehensive income to income from discontinued operations. Following the sale, no balance remained related to foreign currency translation in accumulated other comprehensive income.

On August 29, 2025, the Company also entered into a Transition and Transaction Bonus Agreement with its former Chief Executive Officer, Robert Wiesenthal, modifying his outstanding equity awards. A total of 2,950,219 previously granted performance stock units ("PSUs") and restricted stock units ("RSUs") were amended, consisting of (i) PSUs (the "Earn-out PSUs") that vest based on the level of adjusted EBITDA achieved by the Passenger business for the 12-month measurement period following closing (zero to 150% payout range determined by linear interpolation), and (ii) time-based awards for the 18-month measurement period that vest upon the Company's receipt of the retention earn-out payment under the Joby Purchase Agreement.

The aggregate fair value of the Earn-out PSUs and time-based awards as of August 29, 2025, was $12,742, comprising $2,850 for the Earn-out PSUs and $9,892 for the time-based awards.

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Notes to Unaudited Interim Condensed Consolidated Financial Statements**

*(amounts in thousands, except share and per share data)*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Earn-out PSUs were valued using a risk-neutral Monte Carlo simulation model that simulates risk-adjusted EBITDA outcomes and correlated stock-price paths, incorporating market inputs such as the Company's stock price, volatility, risk-free rates, and credit-adjusted discount rates.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The time-based awards were valued as the Company's closing stock price of $4.37 multiplied by the number of RSUs, adjusted for the probability of the retention earn-out being achieved. As of the closing date, management considered payment of the full retention earn-out probable, and therefore applied the stock price to all awards in determining fair value.

Because the former executive is no longer providing services to the Company as of the sale date, the awards are accounted for as nonemployee awards. The related compensation expense recognized in discontinued operations reflects the $12,742 fair value of the modified awards. The awards vest based on conditions that are not classified as a service, market or performance condition and as a result such awards are classified as a liability. The awards will continue to be remeasured at fair value each reporting period until settlement, with any subsequent changes in fair value recognized in continuing operations. (Refer to Note 5 for additional information on the award modification and valuation methodology.)

The fair value measurements related to the earn-out awards and contingent consideration are classified as Level 3 within the fair-value hierarchy due to the use of unobservable inputs. The Company will assess changes in these fair values at each reporting date, with any adjustments recognized in earnings in the period identified. (Refer to Note 11 for additional information.)

The following table summarizes the results of operations of the Passenger business which are presented as discontinued operations:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Revenue | $32505 | $38815 | $76556 | $83907 |
| Operating expenses |  |  |  |  |
| &nbsp;&nbsp;Cost of revenue | 21495 | 26486 | 53673 | 62152 |
| &nbsp;&nbsp;Software development | 298 | 383 | 1124 | 1410 |
| &nbsp;&nbsp;General and administrative | 2186 | 6543 | 12989 | 23617 |
| &nbsp;&nbsp;Selling and marketing | 1335 | 1848 | 3790 | 5661 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 25314 | 35260 | 71576 | 92840 |
| Operating income (loss) | 7191 | 3555 | 4980 | (8933) |
| Gain on sale and disposal of discontinued operations | 60435 |  | 60435 |  |
| Income (loss) from discontinued operations before income taxes | 67626 | 3555 | 65415 | (8933) |
| Income tax (benefit) on discontinued operations | 553 | (118) | 557 | (150) |
| Net income (loss) from discontinued operations | $67073 | $3673 | $64858 | $(8783) |

---

The tax expense for the three months ended September 30, 2025 is attributable to the sale of the Passenger business and was primarily due to limitations on the utilization of net operating losses in the U.S federal, state and local jurisdictions. U.S. federal net operating losses generated in periods beginning on or after January 1, 2018 can only offset up to 80% of taxable income. Various state and local jurisdictions provide for similar limitations. The tax benefit in the 2024 period was attributed entirely to Blade Monaco.

The cash flows related to discontinued operations have not been segregated and are included in the unaudited interim condensed consolidated statements of cash flows. The following table presents depreciation and amortization, capital expenditures and other non-cash operating activities of the discontinued operations related to the Passenger business:

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Notes to Unaudited Interim Condensed Consolidated Financial Statements**

*(amounts in thousands, except share and per share data)*

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Depreciation and amortization | 259 | 446 | 1285 | 2247 |
| Capital expenditures | 108 | 664 | 296 | 1696 |
| Stock-based compensation | 34 | 277 | 874 | 1140 |
| Gain on sale of Passenger business | (60435) |  | (60435) |  |

---

The following table summarizes the major classes of assets and liabilities which represent only those related to the Passenger business, classified as held for sale presented as discontinued operations at September 30, 2025 and December 31, 2024, respectively:

---

| | | |
|:---|:---|:---|
| | **September 30,<br>2025** | **December 31,<br>2024** |
| Cash and cash equivalents | $— | $2306 |
| Restricted cash |  | 1006 |
| Accounts receivable, net |  | 1769 |
| Prepaid expenses and other current assets |  | 6071 |
| Property and equipment, net |  | 2453 |
| Intangible assets, net |  | 5689 |
| Goodwill |  | 25510 |
| Operating right-of-use asset |  | 6044 |
| Other non-current assets |  | 1319 |
| &nbsp;&nbsp;Total assets of discontinued operations | $— | $52167 |
| Accounts payable and accrued expenses | $— | $3546 |
| Deferred revenue |  | 6656 |
| Operating lease liability - current |  | 2622 |
| Operating lease liability - non-current |  | 3682 |
| Deferred tax liability |  | 185 |
| &nbsp;&nbsp;Total liabilities of discontinued operations | $— | $16691 |

---

During the third quarter of 2025 after meeting the criteria to be classified as held for sale, the Company performed impairment analyses and allocated goodwill to the Passenger business divestiture disposal groups and no impairments were identified. Refer to Note 4 for additional information. During the reporting period that the Passenger business disposal group was classified as held for sale, the Company assessed whether the fair value less cost to sell were less than the carrying value of the disposal group.

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Notes to Unaudited Interim Condensed Consolidated Financial Statements**

*(amounts in thousands, except share and per share data)*

**Note 4 – Goodwill and Intangible Assets**

***Goodwill***

The changes in the carrying value of goodwill are as follows:

---

| | |
|:---|:---|
| Goodwill balance, December 31, 2024 | $15540 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additions (1) | 69067 |
| Goodwill balance, September 30, 2025 | $84607 |

---

(1) Additions represent goodwill associated with the acquisition of Keystone. See Note 2 for additional information.

***Intangible Assets***

The following table presents information about the Company's intangible assets as of:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | | **September 30, 2025** | **September 30, 2025** | **September 30, 2025** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** |
| |<br>**Estimated Useful Life** | **Gross**<br>**Carrying**<br>**Amount** | **Accumulated**<br>**Amortization** | **Net** | **Gross**<br>**Carrying**<br>**Amount** | **Accumulated**<br>**Amortization** | **Net** |
| &nbsp;&nbsp;Customer list (1) | 3-10 years | $43400 | $(4323) | $39077 | $10600 | $(3533) | $7067 |
| &nbsp;&nbsp;Trademarks (1) | 6-10 years | 9800 | (678) | 9122 | 1000 | (556) | 444 |
| &nbsp;&nbsp;Developed technology (1) | 3 years | 2044 | (489) | 1555 | 726 | (273) | 453 |
| &nbsp;&nbsp;&nbsp;Total |  | $55244 | $(5490) | $49754 | $12326 | $(4362) | $7964 |

---

(1) Includes preliminary estimates of intangible assets associated with the acquisition of Keystone. In 2025, customer list and developed technology, respectively, include intangibles associated with the acquisition of Trinity in 2021.

For the three months ended September 30, 2025 and 2024, amortization of its finite-lived intangible assets were $364 and $275, respectively. For the nine months ended September 30, 2025 and 2024, amortization of its finite-lived intangible assets were $1,128 and $961, respectively.

As of September 30, 2025, the estimated amortization expense of its finite-lived intangible assets for each of the next five years are as follows:

---

| | |
|:---|:---|
| **For the Year Ended December 31,** | |
| 2025 | $1491 |
| 2026 | 5963 |
| 2027 | 5850 |
| 2028 | 5493 |
| 2029 | 5206 |
| Thereafter | 25751 |
| &nbsp;&nbsp;Total | $49754 |

---

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Notes to Unaudited Interim Condensed Consolidated Financial Statements**

*(amounts in thousands, except share and per share data)*

**Note 5 – Stock-Based Compensation**

***Stock Option Awards***

All of the outstanding stock option awards are fully vested. To date, there have been no stock option awards granted under the Strata Critical Medical, Inc. 2021 Omnibus Incentive Plan (f/k/a the Blade Air Mobility, Inc. 2021 Omnibus Incentive Plan) (the "Plan").

Following is a summary of stock option activities for the nine months ended September 30, 2025:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Options** | **Weighted<br>Average<br>Exercise Price** | &nbsp;&nbsp;**Weighted**<br>**Average**<br>**Grant Date**<br>**Fair Value** | &nbsp;&nbsp;&nbsp;**Weighted**<br>**Average**<br>**Remaining**<br>**Life**<br>**(years)** | **Intrinsic**<br>**Value** |
| Outstanding – January 1, 2025 | 5124516 | $0.19 | $0.23 | 3.0 |  |
| &nbsp;&nbsp;Exercised | (1977499) | 0.18 | 0.12 |  | $6173 |
| &nbsp;&nbsp;Expired | (21840) | 0.31 | 0.11 |  |  |
| Outstanding – September 30, 2025 | 3125177 | $0.19 | $0.31 | 3.3 | $11997 |
| Exercisable as of September 30, 2025 | 3125177 | $0.19 | $0.31 | 3.3 | $11997 |

---

***Restricted Stock Units***

During the nine months ended September 30, 2025, the Company granted an aggregate of 5,749,265 restricted stock units ("RSUs"), of which 2,382,691 were to various employees, officers, directors, consultants, and service providers and 3,366,574 were performance-based restricted stock units ("PSUs") granted to named executive officers and key employees under the Plan (as defined above).

The RSUs have various vesting dates, ranging from vesting on the grant date to as late as four years from the date of grant.

The PSUs granted in the nine months ended September 30, 2025 are tied to multi-year financial targets. The PSUs granted in March 2025 have a three-year service period ending on December 31, 2027 and a grant-date fair value of $3.01 per share, while the PSUs granted in August 2025 have a performance period ending September 30, 2028 and a grant-date fair value of $4.37 per share. These awards vest based on the achievement of specified Adjusted EBITDA and Free Cash Flow targets, subject to the executives continued service through the applicable performance period. Each PSU represents the right to receive one share of the Company's common stock.

Compensation expense associated with PSUs is recognized over the service period of the awards that are ultimately expected to vest when the related performance objective is met. The estimate of the number of awards expected to vest is reassessed each reporting period.

*Modification of Awards in Connection With Passenger Business Sale*

In connection with the sale of the Company's Passenger business completed on August 29, 2025, all equity awards held by the former Chief Executive Officer were modified. Because the new awards relate to the disposed business and no further service is provided to the Company, the associated compensation costs were included within discontinued operations. Refer to Note 3 for additional information regarding the modification and valuation of these awards. In addition, the modification resulted in a credit of $2,873 representing the reversal of previously recognized expense on unvested awards. This credit was included in continuing operations as it relates to services provided by the former Chief Executive Officer prior to his transfer to Joby Buyer.

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Notes to Unaudited Interim Condensed Consolidated Financial Statements**

*(amounts in thousands, except share and per share data)*

---

| | | |
|:---|:---|:---|
|  | **Restricted Stock Units** | **Weighted Average Grant Date**<br>**Fair Value** |
| Non-vested – January 1, 2025 | 9286110 | $4.10 |
| &nbsp;&nbsp;&nbsp;&nbsp;Granted  | 5749265 | 3.00 |
| &nbsp;&nbsp;&nbsp;&nbsp;Vested | (3468117) | 4.06 |
| &nbsp;&nbsp;&nbsp;&nbsp;Forfeited | (1179652) | 3.72 |
| Non-vested – September 30, 2025 (1) | 10387606 | $3.85 |

---

(1) 4,461,115 are PSUs that will vest subject to the achievement of Adjusted EBITDA and Free Cash Flow goals by the Company as discussed above. Includes 2,950,219 awards (RSUs and PSUs) held by the Company's former Chief Executive Officer that were modified in connection with the sale of the Passenger business. The modification changed the vesting conditions but did not affect the number of awards outstanding. See Note 3 for additional information.

As of September 30, 2025, unamortized stock-based compensation costs related to restricted share arrangements was $22,256 and will be recognized over a weighted average period of 2.1 years.

***Stock-Based Compensation Expense***

Stock-based compensation expense for stock options and restricted stock units in the unaudited interim condensed consolidated statements of operations is summarized as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Software development  | $77 | $118 | $307 | $199 |
| General and administrative (1) | 1505 | 4806 | 9933 | 13587 |
| Selling and marketing | 64 | 201 | 132 | 508 |
| Total stock-based compensation expense (2) | $1646 | $5125 | $10372 | $14294 |

---

(1) Includes a credit of $2,873 due to the modification of awards as described above.

(2) Total stock-based compensation expense for the three and nine months ended September 30, 2025 and 2024 include accrued expenses.

**Note 6 – Segment and Geographic Information**

***Segment Information***

Operating segments are defined as components of an enterprise that engage in business activities for which discrete financial information is available that is evaluated regularly by the chief operating decision makers ("CODM") and is used in resource allocation and performance assessments. The Company has identified one operating and reportable segment - Medical, as our co-Chief Executive Officers, who are our CODMs, regularly review discrete information for that reportable segment. The Company's CODMs evaluate the Company's financial information and resources and assess the performance of these resources on a consolidated basis. The measure of segment profit or loss for the Company's single segment is net income (loss), which can be found in the condensed consolidated statement of operations. The Company manages its operations on an integrated basis, focusing on optimizing performance and directing investments to support continued growth across the business. The Company does not allocate assets at the reportable segment level as these are managed on an entity wide group basis and, accordingly, the Company does not report asset information by segments.

Prior to the completion of the sale of the Company's Passenger business on August 29, 2025, the Company operated two reportable segments: (i) Passenger and (ii) Medical. The Passenger segment consisted of the Company's short-distance air transportation and related ground services business, which was sold to Joby Aero, Inc. on August 29, 2025. Following the sale, the Passenger segment is part of discontinued operations in accordance with ASC 205-20, Presentation of Financial Statements—Discontinued Operations, and is no longer included in segment results.

Subsequent to the sale, the Company's continuing operations consist of a single reportable segment, Medical, which provides air and ground logistics, surgical organ recovery, organ placement and normothermic regional perfusion for the

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Notes to Unaudited Interim Condensed Consolidated Financial Statements**

*(amounts in thousands, except share and per share data)*

transplant industry, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers. The Company's Co-Chief Executive Officers serve as the CODMs and regularly review financial information for this consolidated Medical business to allocate resources and assess performance. Accordingly, beginning with the quarter ended September 30, 2025, the Company reports a single operating and reportable segment, Medical.

**Note 7 – Income Taxes** 

The Company's effective tax rate represents the Company's estimated tax rate for the year based on projected income and the mix of income among the various states tax jurisdictions, adjusted for any discrete transactions occurring during the period. The sale of the Company's Passenger business to the Joby Buyer constituted a discrete transaction in the quarter ended September 30, 2025, as did the acquisition of Keystone. There was no tax expense associated with the acquisition of Keystone.

For the three months ended September 30, 2025 and 2024, income tax expense from continued operations was $— and $—, respectively. For the nine months ended September 30, 2025 and 2024, income tax expense from continued operations was $— and $—, respectively.

The Company maintains a full valuation allowance on net deferred tax assets as of September 30, 2025 and December 31, 2024.

On July 4, 2025, the One Big Beautiful Bill Act, a budget reconciliation package that changes the U.S. federal income tax laws, including extensions of various expiring provisions from the Tax Cuts and Jobs Act of 2017, was signed into law. The Company expects no material impact of the legislation and forthcoming administrative guidance and regulations to our financial statements and results of operations .

**Note 8 – Earnings per Common Share**

The Company has granted restricted stock awards with dividend rights that are considered to be participating securities. Accordingly, a portion of the Company's earnings is allocated to those participating securities in the earnings per share ("EPS") calculation under the two-class method. Basic earnings per common share is computed using the two-class method by dividing income available to common stockholders after the allocation of dividends and undistributed earnings to the participating securities by the weighted average number of common shares outstanding for the period. Diluted earnings per common share is calculated using the more dilutive of the treasury stock method or the two-class method. Diluted earnings per common share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised and is computed after giving consideration to the weighted average dilutive effect of the Company's stock options, warrants, and nonvested restricted stock, where applicable. Diluted EPS under the two-class method also considers the allocation of earnings to the participating securities. Antidilutive securities are disregarded in earnings per share calculations. Diluted EPS shown below reflects the two-class method, as diluted EPS under the two-class method was more dilutive than under the treasury stock method.

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Notes to Unaudited Interim Condensed Consolidated Financial Statements**

*(amounts in thousands, except share and per share data)*

A reconciliation of net loss and common share amounts used in the computation of basic and diluted income (loss) per common share is presented below.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| **Numerator:** |  |  |  |  |
| Net loss from continuing operations | $(9657) | $(5627) | $(14678) | $(8731) |
| Net income (loss) from discontinued operations | 67073 | 3673 | 64858 | (8783) |
| &nbsp;&nbsp;Net income (loss) | $57416 | $(1954) | $50180 | $(17514) |
| **Denominator:** |  |  |  |  |
| Total weighted-average common shares outstanding | 82454657 | 78044254 | 81223912 | 77151361 |
| **Basic and diluted earnings (loss) per share** |  |  |  |  |
| &nbsp;&nbsp;Continuing operations | $(0.12) | $(0.07) | $(0.18) | $(0.11) |
| &nbsp;&nbsp;Discontinued operations | 0.81 | 0.05 | 0.80 | (0.11) |
| Total basic and diluted earnings (loss) per share | $0.70 | $(0.03) | $0.62 | $(0.23) |

---

The following table represents common stock equivalents that were excluded from the computation of diluted loss per common share for the three and nine months ended September 30, 2025 and 2024 because the effect of their inclusion would be anti-dilutive:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Warrants to purchase shares of common stock | 14166644 | 14166644 | 14166644 | 14166644 |
| Options to purchase shares of common stock | 3125177 | 6526611 | 3125177 | 6526611 |
| Outstanding earn-out shares (1) | 1717303 |  | 1717303 |  |
| Restricted shares of common stock | 10387606 | 10112365 | 10387606 | 10112365 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total potentially dilutive securities | 29396730 | 30805620 | 29396730 | 30805620 |

---

(1) Pursuant to the Company's acquisition of Keystone, 1,717,303 shares were issued and outstanding and transferred to an escrow agent at the close of the acquisition. While these shares are legally issued and outstanding, they are excluded from the weighted average shares outstanding calculation because they are contingently returnable based on the determination of Keystone's 2025 final Adjusted EBITDA discussed above.

**Note 9 – Commitments and Contingencies**

***Capacity Purchase Agreements***

The Company has contractual relationships with various aircraft operators to provide aircraft service. Under these capacity purchase agreements ("CPAs"), the Company pays the operator contractually agreed fees (carrier costs) for operating these flights. The fees are generally based on fixed hourly rates for flight time multiplied by hours flown. Under these CPAs, the Company is also responsible for landing fees and other costs, which are either passed through by the operator to the Company without any markup or directly incurred by the Company.

As of September 30, 2025, the Company has total remaining unfulfilled obligations of $3,191 for the years ended December 31 2025 and 2026. The remaining unfulfilled obligation includes amounts within operating lease liability related to aircraft leases embedded within our capacity purchase agreements as included in the operating right-of-use asset and lease liability.

***Legal and Environmental***

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Notes to Unaudited Interim Condensed Consolidated Financial Statements**

*(amounts in thousands, except share and per share data)*

From time to time, we may be a party to litigation that arises in the ordinary course of business. Other than described below, we do not have any pending litigation that, separately or in the aggregate, would, in the opinion of management, have a material adverse effect on its results of operations, financial condition or cash flows. As of September 30, 2025, management believes, after considering a number of factors, including (but not limited to) the information currently available, the views of legal counsel, the nature of contingencies to which the Company is subject and prior experience, that the ultimate disposition of these other litigation and claims will not materially affect the Company's consolidated financial position or results of operations. The Company records liabilities for legal and environmental claims when a loss is probable and reasonably estimable. These amounts are recorded based on the Company's assessments of the likelihood of their eventual disposition. The Company's view and estimates related to these matters may change in the future, as new events and circumstances arise and as the matters continue to develop.

In February 2024, two putative class action lawsuits relating to the acquisition of Blade Urban Air Mobility, Inc. ("Old Blade") were filed in the Delaware Court of Chancery. On April 16, 2024, these cases were consolidated under the caption Drulias et al. v. Affeldt, et al., C.A. No. 2024-0161-SG (Del. Ch.) ("*Drulias*"). Plaintiffs assert claims for breach of fiduciary duty and unjust enrichment claims against the former directors of Experience Investment Corp. ("EIC" and such directors, the "EIC Directors"), the former officers of EIC, and Experience Sponsor LLC ("Sponsor"), and aiding and abetting breach of fiduciary duty claim against Sponsor. The operative complaint alleges, amongst other things, that the proxy statement related to the acquisition of Old Blade insufficiently disclosed EIC's cash position, Old Blade's value prospects and risks, and information related to Old Blade's chief executive officer, who was also the Company's former chief executive officer. The consolidated complaints seeks, among other things, damages and attorneys' fees and costs. Litigation is ongoing. The Company included a provision for the expected resolution in the condensed consolidated statement of operations.

**Note 10 – Warrant Liabilities**

On May 7, 2021, the merger between Old Blade and EIC was consummated (the "Merger"). The warrants acquired in the Merger include (a) redeemable warrants issued by EIC and sold as part of the units in the EIC Initial Public Offering ("EIC IPO") (whether they were purchased in the EIC IPO or thereafter in the open market), which are exercisable for an aggregate of 9,166,644 shares of common stock at a purchase price of $11.50 per share (the "Public Warrants") and (b) warrants issued by EIC to Sponsor in a private placement simultaneously with the closing of the EIC IPO, which are exercisable for an aggregate of 5,000,000 shares of common stock at a purchase price of $11.50 per share (the "Private Placement Warrants").

The Company evaluated its warrants under ASC 815-40, *Derivatives and Hedging—Contracts in Entity's Own Equity*, and concluded that they do not meet the criteria to be classified in stockholders' equity. Accordingly, the Company classifies the warrants as liabilities at their fair value and adjusts the warrants to fair value at each reporting period. This liability is subject to remeasurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company's unaudited interim condensed consolidated statements of operations. See Note 11 – Fair Value Measurements for additional information.

***Warrants*** — Public Warrants may only be exercised for a whole number of shares. The Public Warrants became exercisable on June 7, 2021. The Public Warrants will expire on May 7, 2026 or earlier upon redemption or liquidation.

*Redemptions of Warrants for Cash* — The Company may redeem the Public Warrants:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• in whole and not in part;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• at a price of $0.01 per warrant;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• upon not less than 30 days' prior written notice of redemption to each warrant holder; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• if, and only if, the reported last sale price of the Company's common stock equals or exceeds $18.00 per share for any 20 trading days within a 30-trading day period ending three business days before the Company sends the notice of redemption to each warrant holder.

*Redemption of Warrants for Shares of Common Stock* — The Company may redeem the outstanding warrants:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• in whole and not in part;

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Notes to Unaudited Interim Condensed Consolidated Financial Statements**

*(amounts in thousands, except share and per share data)*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• at a price equal to a number of shares of common stock to be determined, based on the redemption date and the fair market value of the Company's common stock;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• upon a minimum of 30 days' prior written notice of redemption;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• if, and only if, the last reported sale price of the Company's common stock equals or exceeds $10.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations, and the like) on the trading day prior to the date on which the Company sends the notice of redemption to the warrant holders; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• if, and only if, there is an effective registration statement covering the shares of common stock issuable upon exercise of the warrants and a current prospectus relating thereto is available throughout the 30-day period after the written notice of redemption is given.

If the Company calls the Public Warrants for redemption for cash, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a "cashless basis", as described in the warrant agreement. The exercise price and number of shares of common stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, recapitalization, reorganization, merger, or consolidation. However, except as described below, the warrants will not be adjusted for issuance of common stock at a price below its exercise price. Additionally, in no event will the Company be required to net-cash settle the warrants.

The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the initial public offering, except that the Private Placement Warrants will be exercisable on a cashless basis and be non-redeemable so long as they are held by the initial purchasers or their permitted transferees (unless the Company's common stock equals or exceed $10 per share and the Company redeems all the Public Warrants). If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.

**Note 11 – Fair Value Measurements**

The following table presents information about the Company's assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2025 and December 31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.

---

| | | | |
|:---|:---|:---|:---|
| | **Level** | **September 30, 2025** | **December 31, 2024** |
| **Assets** | | | |
| Money market fund (1) | 1 | $15592 | $13751 |
| Contingent consideration asset (2) | 3 | 27825 |  |
| Indemnity holdback related to sale of business (2) | 3 | 8575 |  |
| Total assets at fair value |  | $51992 | $13751 |
| **Liabilities** |  |  |  |
| Warrant liabilities - Public Warrants | 1 | $1906 | $3758 |
| Warrant liabilities - Private Warrants | 2 | 1040 | 2050 |
| Share-based payment liability-classified (3) | 3 | 12742 |  |
| Equity consideration in escrow and contingent consideration (4) | 3 | 9214 |  |
| Total liabilities at fair value |  | $24902 | $5808 |

---

(1) As of September 30, 2025 and December 31, 2024, the Company had cash equivalents held in a money market fund. The Company has concluded that due to the highly liquid nature of the fund, the carrying value approximates fair value, which represents a Level 1 input. The balance of cash equivalents held in the money market fund is included in cash and cash equivalents.

(2) Contingent consideration and indemnity holdback related to sale of business, presented under "Other Non-Current Assets", in the unaudited interim condensed consolidated balance sheets, was established during the period ended September 30, 2025. Refer to Note 3 for additional information.

(3) Share-based payment liability-classified is presented under "Other Non-Current Liabilities", in the unaudited interim condensed consolidated balance sheets, was established during the period ended September 30, 2025. Refer to Note 3 for additional information.

(4) Equity consideration in escrow and contingent consideration is presented under "Accounts payable and Accrued Expenses" and "Other Non-Current Liabilities" as applicable, in the unaudited interim condensed consolidated balance sheets, was established during the period ended September 30, 2025. Refer to Note 2 for additional information.

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Notes to Unaudited Interim Condensed Consolidated Financial Statements**

*(amounts in thousands, except share and per share data)*

***Fair Value of Warrant Liabilities***

The Warrants were accounted for as liabilities in accordance with ASC 815-40 and are presented within "Warrant liability" on the Company's unaudited interim condensed consolidated balance sheets. The warrant liabilities are measured at fair value upon initial recognition and on a recurring basis, with changes in fair value presented within "Change in fair value of warrant liabilities" in the unaudited interim condensed consolidated statements of operations.

The Public Warrants are considered part of Level 1 of the fair value hierarchy, as those securities are traded on an active public market. At May 7, 2021 and thereafter, the Company valued the Private Warrants using Level 2 of the fair value hierarchy. The Company used the value of the Public Warrants as an approximation of the value of the Private Warrants as they are substantially similar to the Public Warrants, but not directly traded or quoted on an active market.

Subsequent Measurement

The following table presents the changes in fair value of the warrant liabilities:

---

| | | | |
|:---|:---|:---|:---|
| | **Public**<br>**Warrants** | &nbsp;&nbsp;&nbsp;**Private** <br>**Placement**<br>**Warrants** | **Total Warrant**<br>**Liability** |
| Fair value as of January 1, 2025 | $3758 | $2050 | $5808 |
| Change in fair value of warrant liabilities | (1852) | (1010) | (2862) |
| Fair value as of September 30, 2025 | $1906 | $1040 | $2946 |

---

**Note 12 – Stockholders' Equity**

***Preferred Stock***

The Board of Directors of the Company (the "Board") is authorized to provide, out of the unissued shares of Preferred Stock, for one or more series of Preferred Stock and, with respect to each such series, to fix, without further stockholder approval, the number of shares constituting such series and the designation of such series, the powers (including voting powers), preferences and relative, participating, optional and other special rights, and the qualifications, limitations or restrictions thereof, of such series of Preferred Stock. The powers (including voting powers), preferences and relative, participating, optional and other special rights of, and the qualifications, limitations or restrictions thereof, of each series of Preferred Stock, if any, may differ from those of any and all other series at any time outstanding. There was no preferred stock issued and outstanding as of September 30, 2025 or December 31, 2024.

***Share Repurchase Program***

On March 20, 2024, the Company announced that its Board had authorized a stock repurchase program, pursuant to which the Company may repurchase, from time to time, up to an aggregate of $20.0 million of the Company's common stock, exclusive of any fees, commissions or other expenses related to such repurchases. The repurchase program expired on March 31, 2025. There were no repurchases of any shares of common stock under the program during the period from January 1, 2025 through its expiration on March 31, 2025. The Company repurchased approximately $0.2 million of common stock during 2024 under this program.

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

**Item 2. Management's discussion and analysis of financial condition and results of operations**

*The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited interim condensed consolidated financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q and our audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2024.* 

*In addition to historical consolidated financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, and beliefs.*

**Forward-Looking Statements**

This Quarterly Report on Form 10-Q may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can generally be identified using forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "seeks", "projects", "intends", "plans", "may", "will" or "should" or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. They appear in several places throughout this report and include statements regarding our intentions, beliefs or current expectations concerning, among other things, results of operations, financial condition, liquidity, prospects, growth, strategies and the markets in which we operate. Such forward-looking statements are based on available current market material and management's expectations, beliefs, and forecasts concerning future events impacting us and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and generally beyond our control. Actual results and the timing of events may differ materially from the results anticipated in these forward-looking statements.

Our operations and financial results are subject to various risks and uncertainties. The following are among those factors, but are not the only factors, that could adversely affect us and/or that may cause actual results to differ materially from such forward-looking statements:

<u>Risks Related to Our Business and Growth Strategy</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• continued occurrence of net losses, which we have experienced since inception;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the impact of our recently completed divestment of the Passenger business and acquisition of Keystone (as defined below) and our ability to realize the anticipated benefits of these transactions, including the receipt of contingent consideration in connection with the sale of the Passenger business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• any change to the ownership of our aircraft and the operational and business challenges related thereto;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• effects of competition;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• harm to our reputation and brand;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to provide high-quality customer support;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our reliance on contractual relationships with certain transplant centers, hospitals and Organ Procurement Organizations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• reliance on certain customers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• competition from providers with proprietary organ preservation technology or additional capabilities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the continuing availability of organ donors and viable donor organs;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• insufficient reimbursement and funding for organ transport costs;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• risks related to organ transport operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• new technology that could make ground or commercial air transport of organs more viable;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• negative publicity, reputational damage, litigation, claims or investigations relating to our provision of clinical services and perfusion staffing services;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• regulatory changes, legislative reforms, and civil or criminal enforcement actions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to successfully integrate Keystone and to identify, complete and successfully integrate future acquisitions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• impact of natural disasters, outbreaks and pandemics, economic, social, weather, growth constraints, geopolitical, and regulatory conditions or other circumstances on metropolitan areas and airports where we have geographic concentration;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• any adverse publicity stemming from accidents involving small aircraft, helicopters or charter flights and, in particular, any accidents involving our third-party operators;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the effects of climate change;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• terrorist attacks, geopolitical conflict or security events;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the availability of aircraft fuel;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to access additional funding to finance our operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to manage our growth;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• increases in insurance costs or reductions in insurance coverage;

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the loss of key members of our management team;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to maintain our company culture;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• effects of fluctuating financial results and the fact that the Company's historical financial statements included in prior periodic reports may not be comparable due to the impact of discontinued operations;

<u>Risks Related to Our Dependence on Third-Party Providers</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our reliance on third-party operators to provide and operate aircraft;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the availability of third-party aircraft operators to match demand;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• disruptions to third-party operators and providers workforce;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the possibility that our third-party aircraft operators may illegally, improperly or otherwise inappropriately operate

our branded aircraft;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our reliance on third-party web service providers;

<u>Risks Related to Intellectual Property, Cybersecurity, Information Technology and Data Management Practices</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to address system failures, defects, errors or vulnerabilities in our website, applications, backend systems or other technology systems or those of third-party technology providers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• interruptions or security breaches of our information technology systems, especially with the continued development and increased usage of artificial intelligence (AI);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our placements within mobile operating systems and application marketplaces;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to protect our intellectual property rights;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our use of open source software;

<u>Legal and Regulatory Risks Related to Our Business</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• changes in our regulatory environment;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the impact of any litigation or regulatory investigations that we may be subject to;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• regulatory obstacles in local governments;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to comply with domestic and foreign privacy, data protection, consumer protection and security laws;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the expansion of environmental regulation;

<u>Other Risks</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to remediate any material weaknesses or maintain effective internal controls over financial reporting;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to maintain effective internal controls and disclosure controls; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the other factors described elsewhere in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2024, included under the headings "Risk Factors," "Management's Discussion and Analysis of Financial Condition" or as described in the other documents and reports we file with the SEC.

Actual results, performance or achievements may differ materially, and potentially adversely, from any forward-looking statements and the assumptions on which those forward-looking statements are based. There can be no assurance that the data contained herein is reflective of future performance to any degree. You are cautioned not to place undue reliance on forward-looking statements as a predictor of future performance. All information set forth herein speaks only as of the date hereof and we disclaim any intention or obligation to update any forward-looking statements, whether as a result of new information, changes in expectations, future events or otherwise.

**Overview** 

Strata Critical Medical, Inc. ("Strata" or the "Company") is a time-critical logistics and medical services provider to the United States healthcare industry. The Company operates one of the nation's largest air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated "one call" solution for donor organ recovery. Strata's core services include air and ground logistics, surgical organ recovery, organ placement and normothermic regional perfusion for the transplant industry, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers, offered under the Trinity Medical Solutions ("Trinity") and Keystone Perfusion brands.

Strata's mission is to increase the number of organs that are successfully transplanted while leveraging the Company's expertise and resources to provide other medical and logistics services to a broader customer base. Strata's goals are closely aligned with those of all participants in the transplant ecosystem, including transplant centers, regulators, Organ Procurement Organizations ("OPOs") and other service providers. We believe that, by working with Strata, industry participants can save money, save more lives and operate more efficiently.

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

Strata operates in a single segment, offering a variety of logistics and clinical services related to organ transplant and the broader healthcare industry. All of Strata's services are provided to transplant centers, organ procurement organizations, hospitals or other businesses that pay the Company directly.

Transplant Logistics Services

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Air Logistics – Air transportation of human organs for transplant as well as related staff, equipment, blood samples, and tissue samples. Service is typically provided on fixed wing aircraft operating specifically for each individual organ. Strata also offers on-board couriers for commercial flights and "next flight out" shipping coordination.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Ground Logistics - Ground transportation of human organs for transplant as well as related staff, equipment, blood samples, and tissue samples.

Transplant Clinical Services

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Organ Recovery – Surgical procurement of donor organs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Normothermic Regional Perfusion ("NRP") – In situ perfusion of donor organs with oxygenated blood to improve clinical outcomes and enable functional assessment prior to recovery.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Organ Placement – Services related to the evaluation and acceptance of potential donor organs for recipients as well as administrative support with the transplant process.

Other Clinical Services

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Cardiac Care – Cardiac perfusion, blood management & autotransfusion and disposables. Services are typically provided under contract with hospitals to support open-heart surgery procedures.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Other – Extracorporeal Membrane Oxygenation (ECMO) services, perfusion temporary staffing and equipment rental offered to healthcare providers .

Outlined below are recent material transactions impacting this Quarterly Report on Form 10-Q.

*Sale of Passenger business* 

On August 29, 2025, the Company completed the previously disclosed sale of its Passenger business to Joby Aero, Inc. ("Joby Buyer"), pursuant to an Equity Purchase Agreement, dated August 1, 2025 (the "Joby Purchase Agreement"). The Passenger business acquired by the Joby Buyer pursuant to the Joby Purchase Agreement consisted of the Company's business of offering, selling, promoting, marketing, planning, booking, brokering, coordinating and arranging the transportation of passengers on aircraft operated by other entities and related ground transportation services. The purchase price received by the Company upon the consummation of the transactions contemplated by the Joby Purchase Agreement was approximately $76.0 million based on the closing price per share of $14.27 of Joby Aviation Inc's ("Joby Aviation") common stock as of August 28, 2025), after giving effect to certain pre-closing adjustments and indemnity holdbacks pursuant to the terms of the Joby Purchase Agreement, consisting of 5,325,585 shares of Joby Aviation's common stock, par value $0.0001 per share (the "Buyer Shares"). The Company subsequently sold the Buyer Shares received in connection with closing for net proceeds of $70.2 million. The Company may receive up to an additional $35.0 million in consideration upon the satisfaction of certain financial performance and employee retention targets described in the Joby Purchase Agreement during the 12 and 18 months, respectively, following the closing of this transaction, payable in cash or Buyer Shares at Joby Buyer's election, as well as the release of up to $10.0 million in indemnity holdbacks. The number of Buyer Shares issued to the Company, if any, shall be based on the average of the daily volume-weighted average sales price per Buyer Share on the New York Stock Exchange for each of the ten consecutive trading days ending on and including the first trading day preceding the applicable measurement dates described in the Joby Purchase Agreement.

The sale qualified as a discontinued operation under ASC 205-20. The Passenger business acquired by Joby Buyer included all operations previously reported within the Passenger segment, as well as certain assets and activities currently reported within unallocated corporate expenses and software development, including certain costs related to software development personnel, the Company's former CEO and headquarter lease.

The assets and liabilities of the Passenger business as of December 31, 2024 were retrospectively classified as held for sale and presented as discontinued operations. The results of operations for the nine months ended September 31, 2025 and 2024 reflect the financial results of the Passenger business, including activity through August 29, 2025, the transaction date, as discontinued operations. The cash flows and comprehensive income of the Passenger business have not been separately presented and are included in the unaudited interim condensed consolidated statements of cash flows and unaudited interim condensed consolidated statements of comprehensive loss, respectively, for all periods presented. Unless

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

otherwise indicated, the information in the notes to the unaudited interim condensed consolidated financial statements refer only to Strata's continuing operations and do not include discussion of balances or activity of the Passenger business.

*Acquisition of Keystone Perfusion Services, LLC*.***

On September 16, 2025, the Company completed the acquisition of Keystone Perfusion Services, LLC ("Keystone"), an organ recovery and normothermic regional perfusion service provider to the transplant industry, pursuant to a Purchase and Sale Agreement, dated September 16, 2025 (the "Keystone Purchase Agreement"), for the following upfront payments: cash $110.0 million (comprised of $65.6 million paid directly to the seller and $44.3 million directed by the seller to other parties on the close date) and 3,434,609 shares (where 1,717,303 are held in escrow). The purchase consideration price is subject to final adjustment, upward or downward by up to $12.4 million, based on Keystone's actual 2025 Adjusted EBITDA performance, with the adjustment to be determined by March 2026. In addition, potential earn-out payments of up to $23.0 million may be made contingent upon Keystone's achievement of gross profit targets (as defined in the Keystone Purchase Agreement) for each of the years 2026 to 2028. See Note 2 to the unaudited interim condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for additional information.

**Our Business Model**

*Logistics Services*

We typically provide logistics services to transplant centers, organ procurement organizations and other businesses on a contractual basis including provisions stipulating that Strata will be the "first call" for any transportation needs.

Pricing is based on a fixed price per flight hour flown with a fuel cost surcharge above a set benchmark. Ancillary costs such as landing fees and de-icing are passed through to the end customer.

Strata leverages an asset-light air logistics business model: we primarily utilize aircraft that are owned and/or operated by third parties on Strata's behalf. In these arrangements, pilots, maintenance, hangar, insurance, and fuel are all costs borne by our network of operators, which provide aircraft flight time to Strata at fixed hourly rates. This enables our operator partners to focus on training pilots, maintaining aircraft and flying, while we maintain the relationship with our customer from booking through flight arrival.

When utilizing third-party aircraft and/or aircraft operators, we typically pre-negotiate fixed hourly rates and flight times, paying only for flights actually flown, creating a predictable and flexible cost structure. Strata provides guaranteed flight commitments to some of our third-party operators through capacity purchase agreements ("CPAs"), which enable Strata to ensure dedicated access to such aircraft with enhanced crew availability, lower costs and, in many cases, the ability to unlock more favorable rates when flying more than the minimum number of hours we guarantee to the operator. Additionally, a significant portion of trips are flown by safety-vetted operators to whom we make no commitments, providing us with additional flexible capacity for high demand periods.

Over the course of 2024, we acquired ten fixed wing aircraft. We made the decision to invest in a limited number of owned aircraft based in high-volume geographies as we believe direct asset ownership will enable (i) improved economies of scale; (ii) increased uptime, enabling more reliable service and higher asset utilization; and (iii) the ability to compete for certain contracts where asset ownership is preferred or required. All of these aircraft are operated and maintained by third-party service providers under Strata's oversight. We prioritize the use of owned aircraft and dedicated aircraft under CPAs, which provide better economies of scale. We size our owned fleet and our commitments under CPAs significantly below our expected demand, enabling us to maximize utilization on those aircraft while fulfilling incremental demand through our network of non-dedicated operators.

We provide ground logistics using a combination of owned vehicles, which are allocated to hub positioned near our customers across the United States, and third-party providers.

We utilize a combination of company employees and contractors as couriers to facilitate the transportation of organs, typically kidneys, aboard scheduled commercial flights. For next flight out services, where kidneys are placed in the cargo hold of a commercial flight, we coordinate with third-party providers on behalf of our customer.

*Clinical Services*

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

We employ perfusionists and transplant surgeons that are primarily dedicated to a specific customer in a particular geography. We own perfusion equipment which is often provided as part of our services or offered through a traditional leasing arrangement.

Our clinical work for Organ Procurement Organizations ("OPOs") typically consists of surgical recovery, NRP services and related equipment provided on a contractual basis with a combination of retainer and per case fees.

For transplant centers, surgical recovery and NRP services are typically provided on an ad hoc basis with pricing on a per case basis. We leverage surgeons, perfusionists and equipment in place to support our OPO customers to provide more efficient options to transplant centers, utilizing locally available resources wherever possible to avoid incremental logistics costs.

For cardiac care hospitals, we typically provide perfusion staffing, often combined with perfusion equipment, on a contractual basis with a combination of retainer and per case fees.

Organ placement services are provided on a contractual basis with a fixed monthly fee based on the size of the customer's program.

*Technology*

We also utilize proprietary technology to manage staffing, training and chain of custody, as well as help customers streamline organ evaluation, procurement and logistics. Our technology enhances the efficiency and cost-effectiveness of our service offerings, further strengthening our position in the organ transportation industry.

**Factors Affecting our Performance** 

***Availability of Donor Organs***

The majority of our business is directly tied to the volume of heart, liver and lung transplants performed in the United States, which is driven primarily by the supply of donor organs that become available.

In recent years, the supply of donor organs has increased consistently, driven primarily by (i) increased utilization of Donation after Circulatory Death ("DCD"), which has expanded the pool of eligible donors; (ii) advancements in technology, including machine and regional perfusion; and (iii) regulatory changes enabling more efficient allocation of organs to recipients with higher need. However, there is no guarantee that this growth will continue, for example, recent months have shown decreased availability of donor organs.

The supply of donor organs is subject to numerous factors outside our control, including changes in organ donation rates, advancements in medical technology, legislative, regulatory or policy changes affecting organ procurement and allocation, and shifts in public attitudes toward organ donation. Additionally, unforeseen events such as pandemics, public health crises, or changes in accident rates may impact the availability of donor organs. If the supply of viable organs declines or if legislative, regulatory or policy changes limit our ability to efficiently transport them, our medical transport business could be adversely affected, which could negatively impact our financial condition and growth prospects.

***Ability to Attract and Retain Customers***

We primarily serve transplant centers, organ procurement organizations and hospitals. Logistics for the hearts, lungs and livers that make up the vast majority of our business is typically requested only hours before the required departure time. Our ability to successfully fulfill these requests with consistent pricing on the requested aircraft type is the primary metric by which our customers evaluate our logistics performance.

The organ logistics marketplace is highly competitive and we compete primarily on our ability to provide reliable, end-to-end air and ground transportation at competitive pricing. Increasingly, we compete directly with manufacturers of organ preservation equipment that also offer transportation or with providers that offer additional services, such as surgical organ recovery, that our customers find valuable.

We have responded to customer demand by introducing new services through our acquisition of Keystone, which enabled us to provide surgical recovery, NRP and other related clinical services as part of an end-to-end offering. We have also added new offerings organically, such as our TOPS organ placement offering, whereby we assist customers in evaluating

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

the suitability of potential donor organs for transplant. However, customers may still demand services or technology that we cannot provide, which could have a material adverse effect on our business, results of operations, and financial condition.

The market for our clinical service offerings, including surgical organ recovery, organ placement, and perfusion, both for transplant and for cardiac care hospitals, is also highly competitive. We compete primarily on our ability to provide high-quality, reliable service integrating electronic recordkeeping to demonstrate compliance with best practices. Specifically for our transplant-related clinical services, we also compete on our ability to integrate our logistics and clinical offerings, resulting in more streamlined communication and efficient transportation, saving time and money for our customers.

***Ability to Secure Aircraft Capacity***

Historically, our ability to aggregate significant demand for flights has been enough to incentivize operators to provide aircraft and crews for our use. However, there is no guarantee that we will continue to be able to secure dedicated aircraft at favorable rates, particularly given significant increases in demand for private jet aircraft in the United States in recent years. Periods of increased demand for private jets have historically led to increased charter costs and more limited availability in the spot jet charter market. Although this has not limited our ability to maintain or increase our access to dedicated jet aircraft at fixed prices in recent periods, there is no guarantee this will continue in the future.

To manage this risk, we enter into long-term capacity purchase agreements with aircraft owners and operators and have purchased a number of jet aircraft, all of which are 100% dedicated to Strata's needs.

***Ability to Hire, Train and Retain Clinicians***

Our surgical recovery, NRP, organ placement and cardiac care offerings depend on our ability to hire, train and retain clinicians, particularly perfusionists and organ recovery surgeons.

Historically, our ability to aggregate demand across transplant centers and cardiac care hospitals has made us an attractive employer for clinicians and enabled us to optimize our staffing model to offer both competitive pricing to customers and attractive pay to our employees. However, given the significant growth in these fields as well as increasing competition, there is no guarantee this will continue.

***Impact of Inflation to our Business***

We generally pay a fixed hourly rate to our third-party operators, based on flight hours flown. These rates are susceptible to inflation and are typically renegotiated on a yearly basis, though some multi-year contracts have fixed rate increases. Some contracts with operators allow for pass-through of fuel price increases above a set threshold. For our owned aircraft, we are more directly exposed to inflation of aircraft operating expenses, including pilot salaries, fuel, insurance, parts and maintenance.

Given significant growth in organ transplant volumes and an increasing percentage of organs that are recovered by commercial surgeons and undergo NRP, demand for clinicians skilled in these procedures is high, resulting in inflation in salaries and fees paid to these practitioners.

We have historically passed through cost inflation to customers and most logistics contracts with customers automatically pass through any fuel surcharges, but there is no guarantee this will continue in the future.

***Seasonality*** 

Our trip volumes are correlated with the overall supply of donor hearts, livers and lungs in the United States, which can be volatile due to a variety of factors. Over the last several years, industry transplant volumes exhibited modest seasonal softness in the calendar third quarter.

**Key Components of the Company's Results of Operations**

***Revenue***

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

Services are typically purchased through our coordinators and are paid for principally via checks and wires. Logistics servicers are typically provided and billed on a fee-for-service basis, clinical services are provided and billed on both fee-for-service and retainer basis. Payments are generally collected after the performance of the related service in accordance with the client's payment terms. A fee-for-service revenue is recognized when the service is completed, retainer revenue is recognized over the retainer contractual term.

***Cost of Revenue***

Cost of revenue consists of costs of operating our aircraft fleet including pilots' salaries, flight costs paid to operators of aircraft and vehicles, depreciation of aircraft, vehicles & medical devices, staff costs associated with providing clinical services and costs of disposable medical products.

***Software Development***

Software development expenses consist primarily of staff costs including stock-based compensation costs and capitalized software amortization costs.

***General and Administrative***

General and administrative expenses consist primarily of staff costs including stock-based compensation, intangibles amortization, depreciation, establishment costs, impairment of intangible assets, insurance costs, pilot training costs for owned aircraft and professional fees.

***Selling and Marketing***

Selling and marketing expenses consist primarily of staff costs including sales commissions & stock-based compensation and promotion costs.

**Discontinued Operations**

On August 29, 2025, we completed the sale of our Passenger business to the Joby Buyer pursuant to the Joby Purchase Agreement. We determined that the sale of the Passenger business represented a strategic shift that will have a major effect on our operations and financial results. Accordingly, the sale is classified as discontinued operations.

We present discontinued operations when a disposal of a component or group of components represents a strategic shift that will have a major effect on our operations and financial results. The results from discontinued operations of the Passenger business prior to and through its sale are presented as net income (loss) from discontinued operations, net of income taxes, in the unaudited interim condensed consolidated statements of operations and comprehensive loss for all periods presented. The assets and liabilities of the Passenger business have been classified as discontinued operations and segregated for all periods presented in the unaudited condensed consolidated balance sheets. See Note 3 to the unaudited interim condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for additional information.

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

**Results of Operations**

The following table presents our unaudited interim condensed consolidated statements of operations for the periods indicated:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
|  | *(in thousands)* | *(in thousands)* | *(in thousands)* | *(in thousands)* |
| Revenue | $49298 | $36062 | $130354 | $110429 |
| Operating expenses |  |  |  |  |
| &nbsp;&nbsp;Cost of revenue | 37684 | 28554 | 100898 | 85854 |
| &nbsp;&nbsp;Software development | 453 | 417 | 1354 | 1031 |
| &nbsp;&nbsp;General and administrative | 16301 | 13869 | 42954 | 39140 |
| &nbsp;&nbsp;Selling and marketing | 482 | 314 | 1096 | 1025 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 54920 | 43154 | 146302 | 127050 |
| Operating loss from continuing operations | (5622) | (7092) | (15948) | (16621) |
| Other non-operating income (loss) |  |  |  |  |
| &nbsp;&nbsp;Interest income | 1127 | 1764 | 3603 | 5624 |
| &nbsp;&nbsp;Change in fair value of warrant liabilities | 33 | (299) | 2862 | 2266 |
| &nbsp;&nbsp;Realized loss from sales of short-term investments | (5195) |  | (5195) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total other non-operating income (loss) | (4035) | 1465 | 1270 | 7890 |
| Loss from continuing operations before income taxes | (9657) | (5627) | (14678) | (8731) |
| &nbsp;&nbsp;Income tax expense (benefit) from continuing operations |  |  |  |  |
| Net loss from continuing operations | $(9657) | $(5627) | $(14678) | $(8731) |
| &nbsp;&nbsp;Net income (loss) from discontinued operations | 67073 | 3673 | 64858 | (8783) |
| Net income (loss) | $57416 | $(1954) | $50180 | $(17514) |

---

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

***Revenue***

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | |
| | **2025** | **2024** |<br>**% Change** | **2025** | **2024** |<br>**% Change** |
|  | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* |
| Revenue | $49298 | $36062 | 36.7% | $130354 | $110429 | 18.0% |

---

***Comparison of the Three Months Ended September 30, 2025 and 2024***

For the three months ended September 30, 2025 and 2024, revenue increased by $13.2 million, or 36.7%, from $36.1 million in 2024 to $49.3 million in 2025, driven by growth in flight hours, ground transportation, revenue per flight hour and other services, as well as the inclusion of Keystone, acquired in mid-September 2025, which contributed approximately $2.8 million. The increase in flight hours was evenly attributable to both existing and new clients.

***Comparison of the Nine Months Ended September 30, 2025 and 2024***

For the nine months ended September 30, 2025 and 2024, revenue increased by $19.9 million or 18.0%, from $110.4 million in 2024 to $130.4 million in 2025, driven by growth in flight hours, ground transportation, revenue per flight hour and other services, as well as the inclusion of Keystone, acquired in mid-September 2025, which contributed approximately $2.8 million. The increase in flight hours was attributable to both existing and new clients, with several major new contracted clients commencing operations in the second quarter of the year 2025.

***Cost of Revenue***

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | |
| | **2025** | **2024** |<br>**% Change** | **2025** | **2024** |<br>**% Change** |
|  | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* |
| Cost of revenue | $37684 | $28554 | 32.0% | $100898 | $85854 | 17.5% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Percentage of revenue | 76% | 79% |  | 77% | 78% |  |

---

***Comparison of the Three Months Ended September 30, 2025 and 2024***

For the three months ended September 30, 2025 and 2024, cost of revenue increased by $9.1 million, or 32.0%, from $28.6 million during 2024 to $37.7 million in 2025, primarily driven by increased revenue.

Cost of revenue as a percentage of revenues decreased by 3 percentage points from 79% in 2024 to 76% in 2025 driven by higher utilization for our owned fleet following the addition of three aircraft, as well as enhanced operational leverage in ground services.

***Comparison of the Nine Months Ended September 30, 2025 and 2024***

For the nine months ended September 30, 2025 and 2024, cost of revenue increased by $15.0 million, or 17.5%, from $85.9 million during 2024 to $100.9 million during 2025 driven by increased revenue.

Cost of revenue as a percentage of revenues decreased by 1 percentage points from 78% in 2024 to 77% in 2025 attributable primarily to improved operational leverage in ground services with expansion of ground hub, partially offset by elevated maintenance and pilot costs relative to the prior year period for our owned fleet.

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

***Software Development***

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | |
| | **2025** | **2024** |<br>**% Change** | **2025** | **2024** |<br>**% Change** |
|  | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* |
| Software development | $453 | $417 | 8.6% | $1354 | $1031 | 31.3% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Percentage of revenue | 1% | 1% |  | 1% | 1% |  |

---

***Comparison of the Three Months Ended September 30, 2025 and 2024***

For the three months ended September 30, 2025 and 2024, software development costs increased by approximately 8.6%, from $0.4 million during 2024 to $0.5 million in 2025, with minor increases year over year.

***Comparison of the Nine Months Ended September 30, 2025 and 2024***

For the nine months ended September 30, 2025 and 2024, software development costs increased by $0.3 million, or 31.3%, from $1.0 million during 2024 to $1.4 million during 2025, driven by higher amortization of capitalized software costs, as more development projects were completed and entered the amortization phase.

***General and Administrative***

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | |
| | **2025** | **2024** |<br>**% Change** | **2025** | **2024** |<br>**% Change** |
|  | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* |
| General and administrative | $16301 | $13869 | 17.5% | $42954 | $39140 | 9.7% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Percentage of revenue | 33% | 38% |  | 33% | 35% |  |

---

***Comparison of the Three Months Ended September 30, 2025 and 2024***

For the three months ended September 30, 2025 and 2024, general and administrative expense increased by $2.4 million, or 17.5%, from $13.9 million during 2024 to $16.3 million in 2025.

The primary drivers of the increase were legal expenses and advocacy fees provisions related to the *Drulias* lawsuit discussed in "— Legal and Environmental" within Note 9 to the unaudited interim condensed consolidated financial statements included in this Quarterly Report on Form 10-Q, M&A transaction costs related to the acquisition of Keystone, and the addition of Keystone's results in mid-September. This increase was partially offset by a $3.9 million reduction in staff costs, of which $3.5 million related to share-based compensation, primarily reflecting a credit from the forfeiture of grants previously awarded to the former CEO prior to his transfer to the Joby Buyer.

***Comparison of the Nine Months Ended September 30, 2025 and 2024***

For the nine months ended September 30, 2025 and 2024, general and administrative expense increased by $3.8 million or 9.7%, from $39.1 million during 2024 to $43.0 million in 2025.

The primary drivers of the increase were legal and advocacy fee provision associated with the *Drulia*s lawsuit discussed in "—Legal and Environmental" within Note 9 to the unaudited interim condensed consolidated financial statements included in this Quarterly Report on Form 10-Q, M&A transaction costs related to the acquisition of Keystone, the inclusion of Keystone's results beginning in mid-September, and higher owned-aircraft expenses, reflecting nine months of activity in 2025 compared with only six months in 2024, as the program was launched in April 2024. Together, these items accounted for a $7.8 million increase. These increases were partially offset by a $3.8 million reduction in staff costs, of which $3.9 million related to share-based compensation, primarily reflecting a credit from the forfeiture of grants previously awarded to the former CEO prior to his transfer to the Joby Buyer.

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

***Selling and Marketing***

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | |
| | **2025** | **2024** |<br>**% Change** | **2025** | **2024** |<br>**% Change** |
|  | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* |
| Selling and marketing | $482 | $314 | 53.5% | $1096 | $1025 | 6.9% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Percentage of revenue | 1% | 1% |  | 1% | 1% |  |

---

***Comparison of the Three Months Ended September 30, 2025 and 2024***

For the three months ended September 30, 2025 and 2024, selling and marketing expense increased by $0.2 million, or 53.5%, from $0.3 million during 2024 to $0.5 million in 2025. The increase is attributable to higher staff costs due to new hires and increased sales commissions, as well as an increase in promotion costs. This was partially offset by a decrease in share-based compensation.

***Comparison of the Nine Months Ended September 30, 2025 and 2024***

For the nine months ended September 30, 2025 and 2024, selling and marketing expense increased by $0.1 million, or 6.9%, from $1.0 million during 2024 to $1.1 million in 2025. The increase is attributable primarily to new hires and an increase in promotion costs. This was partially offset by a decrease in share-based compensation.

***Other Non-Operating income***

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | |
| | **2025** | **2024** |<br>**% Change** | **2025** | **2024** |<br>**% Change** |
|  | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* |
| Interest income | $1127 | $1764 |  | $3603 | $5624 |  |
| Change in fair value of warrant liabilities | 33 | (299) |  | 2862 | 2266 |  |
| Realized loss from sales of short-term investments | (5195) |  |  | (5195) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total other non-operating income (loss) | $(4035) | $1465 | NM (1) | $1270 | $7890 | (83.9)% |

---

(1) Percentage not meaningful.

***Comparison of the Three Months Ended September 30, 2025 and 2024***

For the three months ended September 30, 2025, total other non-operating income consisted primarily of: (i) $1.1 million interest income, attributable to our short-term investments and our money market funds in the current year period (lower interest income is attributable to lower invested balances compared to the prior year period); and a (ii) $(5.2) million realized loss on the sale of securities received as consideration in the Passenger business divestiture.

For the three months ended September 30, 2024, total other non-operating income consisted of: (i) $1.8 million interest income, attributable to our short-term investments and our money market funds; and (ii) $(0.3) million non-cash loss due to fair value revaluation of warrant liabilities as the value of the warrant liabilities fluctuates with the warrants' market price.

***Comparison of the Nine Months Ended September 30, 2025 and 2024***

For the nine months ended September 30, 2025, total other non-operating income consists of: (i) $3.6 million interest income, attributable to our short-term investments and our money market funds in the current year period (lower interest income is attributable to lower invested balances compared to the prior year period); (ii) $2.9 million non-cash gain due to fair value revaluation of warrant liabilities as the value of the warrant liabilities fluctuates with the warrants' market price; and a (iii) $(5.2) million realized loss on the sale of securities received as consideration in the Passenger business divestiture.

For the nine months ended September 30, 2024, total other non-operating income consisted of: (i) $5.6 million interest income, attributable to our short-term investments and our money market funds; and a (ii) $2.3 million non-cash gain due to fair value revaluation of warrant liabilities as the value of the warrant liabilities fluctuates with the warrants' market price.

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

***Income (loss) from discontinued operations, net of tax***

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | |
| | **2025** | **2024** |<br>**% Change** | **2025** | **2024** |<br>**% Change** |
|  | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* |
| &nbsp;&nbsp;Net income (loss) from discontinued operations | $67073 | $3673 | 1726% | $64858 | $(8783) | NM (1) |

---

(1) Percentage not meaningful.

***Comparison of the Three Months Ended September 30, 2025 and 2024***

For the three months ended September 30, 2025, total net income from discontinued operations was $67.1 million and primarily consisted of: (i) gain on disposal of discontinued operations of $60.4 million, (ii) operating income before tax of $7.2 million attributable to revenue of $32.5 million from air transportation for passengers in the United States and Europe on a by-the-seat and on a full aircraft charter basis, and (iii) $0.6 million tax expenses attributable to the capital gain from the sale of the Passenger business.

For the three months ended September 30, 2024, total net income from discontinued operations was $3.7 million and primarily consisted of: (i) operating income before tax of $3.6 million attributable to revenue of $38.8 million from air transportation for passengers in the United States, Canada and Europe on a by-the-seat and on a full aircraft charter basis, and (ii) deferred tax benefit of $0.1 million.

The year-over-year improvement in operating income before tax, from $3.6 million to $7.2 million, was driven primarily by significant improvement in the profitability of the Europe operations following restructuring in October 2024.

***Comparison of the Nine Months Ended September 30, 2025 and 2024***

For the nine months ended September 30, 2025, total net income from discontinued operations was $64.9 million and primarily consisted of: gain on disposal of discontinued operations of $60.4 million and operating income before tax of $5.0 million attributable to revenue of $76.6 million from air transportation for passengers in the United States and Europe on a by-the-seat and on a full aircraft charter basis.

For the nine months ended September 30, 2024, total net loss from discontinued operations was $(8.8) million and primarily consisted of operating loss before tax of $(8.9) million attributable to revenue of $83.9 million from air transportation for passengers in the United States, Canada and Europe on a by-the-seat and on a full aircraft charter basis.

The year-over-year improvement in operating income before tax, from $(8.9) million to $5.0 million, was driven primarily by a $5.8 million impairment charge associated with Blade Canada during the prior year period coupled with a reduction in associated amortization costs, a significant improvement in the profitability of the European operations following restructuring in October 2024, and a reduction in selling and marketing expense.

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

*Net loss from Continuing Operations, Adjusted EBITDA, Gross Profit, Flight Profit, Gross Margin, and Flight Margin*

The following table presents our condensed consolidated results on a continuing operations basis for net loss from continuing operations, Adjusted EBITDA, Gross Profit, Flight Profit, Gross Margin and Flight Margin results:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | |
| | **2025** | **2024** |<br>**% Change** | **2025** | **2024** |<br>**% Change** |
|  | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* |
| Net loss from continuing operations | $(9657) | $(5627) | 71.6% | $(14678) | $(8731) | 68.1% |
| Adjusted EBITDA (1) | $4214 | $67 | 6189.6% | $7096 | 2677 | 165.1% |
| Gross Profit (1) | $9545 | $5427 | 75.9% | $23198 | $19624 | 18.2% |
| Flight Profit (1) | $11614 | $7508 | 54.7% | $29456 | $24575 | 19.9% |
| Gross Margin (1) | 19.4% | 15.0% |  | 17.8% | 17.8% |  |
| Flight Margin (1) | 23.6% | 20.8% |  | 22.6% | 22.3% |  |

---

(1) See section titled "Reconciliations of Non-GAAP Financial Measures" for more information and reconciliations to the most directly comparable GAAP financial measure.

***Comparison of the Three Months Ended September 30, 2025 and 2024***

*Net loss from continuing operations* increased by $(4.0) million for the three months ended September 30, 2025 from $(5.6) million in the same period of 2024 to $(9.7) million in 2025. See "Results of Operations" above for further discussion.

*Adjusted EBITDA* improved by $4.1 million for the three months ended September 30, 2025 from $0.1 million in the same period of 2024 to $4.2 million in 2025. The improvement is attributable to the revenue growth along with improved flight profit margin in logistics services and further improvement with reduced corporate staff costs.

*Gross Profit* increased by $4.1 million for the three months ended September 30, 2025 from $5.4 million in the same period of 2024 to $9.5 million in 2025.

*Flight Profit* increased by $4.1 million, or 54.7%, for the three months ended September 30, 2025 from $7.5 million in the same period of 2024 to $11.6 million in 2025 attributable to a 36.7% increase in revenue coupled with higher Flight Margin (as discussed below).

*Gross Margin* increased from 15.0% in the three months ended September 30, 2024 to 19.4% in the same period of 2025.

*Flight Margin* increased from 20.8% in the three months ended September 30, 2024 to 23.6% in the same period of 2025, primarily driven by higher utilization for our owned fleet following the addition of three aircraft, as well as enhanced operational leverage in ground services.

***Comparison of the Nine Months Ended September 30, 2025 and 2024***

*Net loss from continuing operations* increased by $5.9 million for the nine months ended September 30, 2025 from $(8.7) million in the same period of 2024 to $(14.7) million in 2025. See "Results of Operations" above for further discussion.

*Adjusted EBITDA* improved by $4.4 million for the nine months ended September 30, 2025 from $2.7 million in the same period of 2024 to $7.1 million in 2025. The improvement is attributable to the revenue growth, with further improvement due to reduced professional fees. Partially offset by increases in staff costs and promotion costs associated with increased sales and revenue growth of our continuing operations.

*Gross Profit* increased by $3.6 million for the nine months ended September 30, 2025 from $19.6 million in the same period of 2024 to $23.2 million in 2025.

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

*Flight Profit* increased by $4.9 million, or 19.9%, for the nine months ended September 30, 2025 from $24.6 million in the same period of 2024 to $29.5 million in 2025 attributable to an 18.0% increase in revenue coupled with slightly higher Flight Margin (as discussed below).

*Gross Margin* remained unchanged at 17.8% in both periods.

*Flight Margin* increased from 22.3% in the nine months ended September 30, 2024 to 22.6% in the same period of 2025, a minimal increase attributable primarily to improved operational leverage in ground services, partially offset by elevated maintenance and pilot costs relative to the prior year period for our owned fleet.

**Reconciliation of Non-GAAP Financial Measures**

Certain non-GAAP measures included in this results of operations review have been derived from amounts calculated in accordance with GAAP but are not themselves GAAP measures. Strata believes that the non-GAAP measures discussed below, viewed in addition to and not in lieu of our reported U.S. GAAP results, provide useful information to investors by providing a more focused measure of operating results, enhance the overall understanding of past financial performance and future prospects, and allow for greater transparency with respect to key metrics used by management in its financial and operational decision making. The non-GAAP measures presented herein may not be comparable to similarly titled measures presented by other companies. These include Adjusted EBITDA, Flight Profit, and Flight Margin, which we define, explain the use of and reconcile to the nearest GAAP financial measure below.

*Adjusted EBITDA*

Adjusted EBITDA is defined as net loss from continued operations adjusted to exclude (1) depreciation and amortization, (2) stock-based compensation, (3) change in fair value of warrant liabilities, (4) interest income (5) income tax, (6) realized gains and losses on short-term investments, (7) impairment of intangible assets and (8) certain other non-recurring items (shown below) that management does not believe are indicative of ongoing Company operating performance and would impact the comparability of results between periods.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
|  | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* |
| **Net loss from continuing operations** | $**(9657)** | $**(5627)** | $**(14678)** | $**(8731)** |
| Add (deduct): |  |  |  |  |
| Depreciation and amortization | 1445 | 833 | 3892 | 2185 |
| Stock-based compensation | 1646 | 5125 | 10372 | 14294 |
| Change in fair value of warrant liabilities | (33) | 299 | (2862) | (2266) |
| Realized loss from sales of short-term investments (1) | 5195 |  | 5195 |  |
| Interest income | (1127) | (1764) | (3603) | (5624) |
| Legal expenses and regulatory advocacy fees (2) | 5045 | 165 | 5748 | 427 |
| Executive severance costs |  | 140 |  | 140 |
| SOX readiness costs |  | 220 |  | 302 |
| M&A transaction costs (3) | 1134 | 85 | 1168 | 169 |
| Corporate staff costs included in the sold Passenger business (4) | 566 | 591 | 1864 | 1781 |
| **Adjusted EBITDA** | $**4214** | $**67** | $**7096** | $**2677** |
| Revenue | $49298 | $36062 | $130354 | $110429 |
| Adjusted EBITDA as a percentage of revenue | 8.5% | 0.2% | 5.4% | 2.4% |

---

(1) Consists of realized loss on the sale of securities of Joby Aviation received in consideration in the Passenger business divestiture.

(2) Includes legal expenses and advocacy fees that we do not consider representative of legal and regulatory advocacy costs that we will incur from time to time in the ordinary course of our business. For the three and nine months ended September 30, 2025 and 2024 these costs were related primarily to the *Drulias* lawsuit (see "— Legal and Environmental" within Note 9 to the unaudited interim condensed consolidated financial statements included in this Quarterly Report on Form 10-Q).

(3) Consists of non-recurring M&A transaction costs including professional fees incurred over a short period of time that do not represent ongoing operating expenses of the business.

(4) Represents corporate staff costs associated with certain employees who transferred to Joby following the sale of the Passenger business on August 29, 2025. This adjustment is intended to present more comparable results by excluding from all the periods costs associated with

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

transferred employees. These employees previously performed certain corporate functions that were not replaced after that date. Under U.S. GAAP (ASC 205-20), such costs were included in Continuing Operations in periods prior to August 29, 2025, because staff costs not directly attributable to discontinued operations must remain in continuing operations, even when the employees depart following a divestiture.

*Flight Profit and Flight Margin*

Flight Profit is calculated as revenue less cost of revenue. Flight Margin is calculated as Flight Profit divided by revenue. Flight Profit and Flight Margin are measures that management uses to assess the performance of the business. The Company believes that Flight Profit and Flight Margin provide a useful measure of the profitability of the Company's operations, as they focus solely on the non-discretionary direct costs associated with generating revenue.

*Gross Profit and Gross Margin*

Gross Profit, which is the most directly comparable GAAP financial measure to Flight Profit, is calculated as revenue less cost of revenue and other costs directly related to revenue generating transactions, including depreciation and amortization, direct staff costs including stock-based compensation and commercial costs. Gross Margin is calculated as Gross Profit divided by revenue. The reconciliation of Revenue to Gross Profit and Gross Profit to Flight Profit can be found in the table below.

*Reconciliation of Revenue to Gross Profit and Gross Profit to Flight Profit*

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
|  | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* |
| Revenue | $49298 | $36062 | $130354 | $110429 |
| Less: |  |  |  |  |
| &nbsp;&nbsp;Cost of revenue (1) | 37684 | $28554 | 100898 | 85854 |
| &nbsp;&nbsp;Depreciation and amortization (2) | 364 | 275 | 1128 | 961 |
| &nbsp;&nbsp;Other (3) | 1705 | 1806 | 5130 | 3990 |
| Gross Profit | $9545 | $5427 | $23198 | $19624 |
| Gross Margin | 19.4% | 15.0% | 17.8% | 17.8% |
| Gross Profit | $9545 | $5427 | $23198 | $19624 |
| Reconciling items: |  |  |  |  |
| &nbsp;&nbsp;Depreciation and amortization (2) | 364 | 275 | 1128 | 961 |
| &nbsp;&nbsp;Other (3) | 1705 | 1806 | 5130 | 3990 |
| Flight Profit | $11614 | $7508 | $29456 | $24575 |
| Flight Margin | 23.6% | 20.8% | 22.6% | 22.3% |

---

(1) Cost of revenue consists of costs of operating our aircraft fleet including pilots' salaries, flight costs paid to operators of aircraft and vehicles, depreciation of aircraft, vehicles & medical devices, staff costs associated with providing clinical services and costs of disposable medical products.

(2) Represents real estate depreciation and intangibles amortization included within general and administrative.

(3) Other costs include logistics and coordination staff costs.

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

**Liquidity and Capital Resources**

***Sources of Liquidity***

As of September 30, 2025 and December 31, 2024, we had total liquidity of $75.9 million and $124.8 million, respectively, consisting of cash and cash equivalents of $22.8 million and $16.1 million, respectively, and short-term investments of $53.2 million and $108.8 million, respectively. In addition, as of September 30, 2025 and December 31, 2024, we had restricted cash of $0.3 million and $0.3 million, respectively. As of September 30, 2025, $53.2 million of short-term investments consisted of securities that are traded in highly liquid markets. The Company had net income of $50.2 million for the nine months ended September 30, 2025. During the nine months ended September 30, 2025, we realized net proceeds of $70.2 million from the sale of Buyer Shares received from the sale of the Passenger business.

With $75.9 million of total liquid funds as of September 30, 2025, we anticipate that we have sufficient funds to meet our current operational needs for at least the next 12 months from the date of filing this Quarterly Report. Although we have not historically sought external sources of financing to help fund our operational needs, we may in the future seek to take advantage of market opportunities to obtain financing on terms we deem attractive.

***Liquidity Requirements***

As of September 30, 2025, the Company had net working capital of $94.6 million, cash and cash equivalents of $22.8 million and short-term investments of $53.2 million. The Company had net loss of $17.5 million for the nine months ended September 30, 2024.

In the course of our business, we have certain contractual relationships with third-party aircraft operators pursuant to which we may be contingently required to make payments in the future. As of September 30, 2025, we had commitments to purchase flights from various aircraft operators with aggregate minimum flight purchase guarantees of $3.2 million for the years ending December 31, 2025 and 2026. See "—Capacity Purchase Agreements" within Note 9 to the unaudited interim condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for additional information. Additionally, the Company has operating lease obligations related to real estate and vehicles with expected annual minimum lease payments of $0.2 million and $0.6 million for the years ending December 31, 2025 and 2026, respectively.

We may be required to make earn-out payments of up to $35.4 million, contingent upon the satisfaction of certain financial

performance targets described in the Keystone Purchase Agreement. This contingent consideration will be payable in a mix

of cash and shares of the Company's common stock as described in the Keystone Purchase Agreement. See Note 2 to the unaudited interim condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for additional information.

Based on our current liquidity, we believe that no additional capital will be needed to execute our current business plan over the next 12 months. Our longer-term liquidity requirement will depend on many factors including the pace of our expansion into new markets, our ability to attract and retain customers for our existing products, capital expenditures and acquisitions.

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

***Cash Flows***

The following table summarizes our cash flows for the periods indicated:

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** |
|  | *(in thousands)* | *(in thousands)* |
| Net cash used in operating activities | $(40607) | $(767) |
| Net cash provided by / (used in) investing activities | 51485 | (4992) |
| Net cash used in financing activities | (7170) | (1885) |
| Effect of foreign exchange rate changes on cash balances | (339) | 29 |
| Net increase (decrease) in cash and cash equivalents and restricted cash | $3369 | $(7615) |

---

*Cash Used In Operating Activities*

For the nine months ended September 30, 2025, net cash used in operating activities was $40.6 million, driven by: a net income of $50.2 million, adjusted for net non-cash charges of $43.3 million; transaction costs paid related to the sale of the Passenger business of $6.0 million; $44.3 million paid in connection with the Keystone acquisition for settlement of seller-assumed liabilities, which were directed to third parties and therefore classified within operating activities; and net $2.8 million of cash provided by changes in our working capital assets and liabilities. The $2.8 million net cash provided by changes in our working capital assets and liabilities was primarily driven by an increase in accounts payable and accrued liabilities of $8.4 million attributable to legal fees provision and other transaction costs, an increase in deferred revenue of $1.6 million; a decrease in prepaid and other current assets of $0.8 million and a decrease in other non-current assets of $0.7 million; partially offset by an increase of $8.6 million in accounts receivable attributable to the revenue growth and the consolidation of Keystone in September 2025.

For the nine months ended September 30, 2024, net cash used in operating activities was $0.8 million, driven by a net loss of $17.5 million, net non-cash charges of $20.0 million and net $3.2 million of cash used by changes in our working capital assets and liabilities. The $3.2 million cash used by changes in our working capital assets and liabilities was primarily driven by a decrease in accounts payable and accrued expenses of $8.3 million, driven by the cash payment for the Trinity contingent consideration compensation and for the 2023 short term incentive plan paid in March 2024 and an increase in accounts receivable of $3.6 million (attributable to the revenue growth) and a decrease in deferred revenue of $0.2 million (driven by Passenger client prepayments and gift cards); partially offset by a decrease in prepaid expenses and other current assets of $8.3 million (driven by the utilization of $9.3 million of prepaid deposits under CPAs with M&N as part of the purchase of seven aircraft, partially offset by new prepayments made to operators in connection with new CPAs) and an decrease in other non-current assets of $0.5 million (driven by a lease deposit refund).

*Cash Provided by Investing Activities*

For the nine months ended September 30, 2025, net cash provided by investing activities was $51.5 million, driven by: $70.2 million of proceeds from the sale of Buyer Shares received from the sale of the Passenger business; partially offset by $65.2 million in cash consideration paid in connection with the Keystone acquisition; $7.9 million in purchases of property and equipment, consisting primarily of a spare engine, aircraft capitalized maintenance costs, purchase of vehicles used for organ ground transportation; $1.3 million in capitalized software development costs; $1.2 million in cash transferred with the sale of the Passenger business and $203.0 million of proceeds from maturities of held-to-maturity investments net of $146.3 million in purchases of held-to-maturity investments.

For the nine months ended September 30, 2024, net cash used in investing activities was $5.0 million, driven by $142.8 million in purchases of held-to-maturity investments, $26.3 million in purchases of property and equipment, consisting primarily of $22.8 million in the acquisition of ten aircraft and related capitalized costs to support the Medical segment, with the remaining in furniture and fixtures for new office space in Arizona used by the logistics business, purchase of vehicles used in generating revenue by the logistics business, $2.2 million in consideration paid for the acquisition of CJK and $1.7 million in capitalized software development costs, partially offset by $168.0 million of proceeds from maturities of held-to-maturity investments.

*Cash Used In Financing Activities*

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

For the nine months ended September 30, 2025, net cash used in financing activities was $7.2 million, driven by $7.3 million cash paid for payroll tax payments on behalf of employees in exchange for shares withheld by the Company; partially offset by $0.1 million of proceeds from the exercise of stock options.

For the nine months ended September 30, 2024, net cash used in financing activities was $1.9 million, reflecting $1.8 million cash paid for payroll tax payments on behalf of employees in exchange for shares withheld by the Company and $0.2 million in repurchases and retirement of common stock under a share repurchase program (expired on March 31, 2025); partially offset by $0.1 million of proceeds from the exercise of stock options.

**Critical Accounting Policies and Significant Judgments and Estimates**

This discussion and analysis of the Company's financial condition and results of operations is based on the Company's consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States of America, or U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported periods. In accordance with U.S. GAAP, the Company bases its estimates on historical experience and on various other assumptions the Company believes are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.

For information on the Company's significant accounting policies and estimates refer to "Management's Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Estimates" in our Annual Report on Form 10-K for the year ended December 31, 2024. Except for the accounting policy related to Business Combinations and Contingent Consideration, as discussed in Note 1 of the unaudited interim condensed consolidated financial statements included in this Quarterly Report on Form 10-Q under the caption "Business Combinations and Contingent Consideration,", and other transaction-related updates, including the recognition of share-based payment and contingent consideration liabilities, there been no material changes to these policies and estimates as of September 30, 2025.

**Item 3. Quantitative and qualitative disclosures about market risk**

There have been no material changes in market risk from the information provided in "Item 7A. Quantitative and Qualitative Disclosures About Market Risk" in our Annual Report on Form 10-K for the year ended December 31, 2024.

**Item 4. Controls and Procedures** 

***Evaluation of Disclosure Controls and Procedures***

As of the end of the period covered by this report, our principal executive officer and principal financial officer evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Our evaluation of internal controls over financial reporting did not include the internal controls of Keystone, which was acquired on September 16, 2025 and is included in our consolidated financial statements for this Quarterly Report on Form 10-Q and constituted approximately 39.9% of total assets as of September 30, 2025 and 2.1% and 2.9% of sales and net loss from continuing operations, respectively, for the nine months ended September 30, 2025. Based on their evaluation of our disclosure controls and procedures, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of September 30, 2025 to provide reasonable assurance that information required to be disclosed by the Company in the reports that we file or submit under the Exchange Act is (a) recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and (b) accumulated and communicated to management, including our principal executive officer and principal financial officer, as appropriate to allow for timely decisions regarding required disclosure.

***Changes in Internal Control over Financial Reporting***

There were no changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15(d)-15(f) promulgated under the Securities Exchange Act of 1934, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting during the period covered by this Quarterly Report on Form 10-Q.

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

***Limitations on Internal Control over Financial Reporting***

An internal control system over financial reporting has inherent limitations and may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

**PART II - OTHER INFORMATION**

**Item 1. Legal Proceedings**

See "—Legal and Environmental" within Note 9 to the unaudited interim condensed consolidated financial statements in Part I, Item 1 for information on legal proceedings.

**Item 1A. Risk Factors**

You should carefully consider the risks described under "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024. These risks could materially affect our business, results of operations or financial condition, cause the trading price of our common stock to decline materially or cause our actual results to differ materially from those expected or those expressed in any forward-looking statements made by, or on behalf of, the Company. On August 29, 2025, we completed the sale of our Passenger business, which included all operations previously reported within our Passenger segment. As a result, the risks described under the caption "Risk Factors—Risks Related to our Passenger Segment" in our Annual Report on Form 10-K for the year ended December 31, 2024 are no longer material to our business or results. Other than as described in this Item 1A, there were no material changes in the risk factors described under "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024. These risks are not exclusive, and additional risks to which we are subject include, but are not limited to, the factors mentioned under "Forward-Looking Statements" and the risks of our businesses described elsewhere in this Quarterly Report on Form 10-Q.

***We provide clinical services for our customers and perfusion staffing services to hospitals and health systems. We may be subject to negative publicity and reputational damage related to the provision of such services, as well as litigation, claims, investigations, other proceedings, which could result in actions including substantial judgments, settlement costs, uninsured liabilities, and investigations.***

We rely significantly on our ability to attract, develop, and retain professionals who possess the skills, experience and, as required, licensure, necessary to perform organ recovery services and perfusion staffing services. Our professionals are involved in clinical services such as surgical recovery, which involves the retrieval of organs from donors, and normothermic regional perfusion services, which are heavily regulated industries. The requirements and protocols for such services are complex and may vary amongst our customers. If there is a negative outcome in a particular case, or if a particular case raises ethical questions or concerns, even if our staff were not directly involved in the case, we may be subject to negative publicity, reputational harm, investigations, litigation, claims, and governmental actions that could have an adverse effect on our operations, financial results, and reputation.

***Any inability to realize the anticipated benefits of the sale of the Passenger business or acquisition of Keystone could negatively impact our stock price and our business and financial results.***

On August 29, 2025, the Company completed the sale of its Passenger business to the Joby Buyer and on September 16, 2025, the Company completed the acquisition of Keystone. We completed these transactions with the expectation that they will result in various benefits to us, but such anticipated benefits are subject to a number of uncertainties, including our ability to timely realize cost efficiencies and accretive benefits and our ability to successfully integrate Keystone and retain its key employees and clients. Failure to achieve these anticipated benefits could result in decreases in the amount of expected revenues and diversion of management's time and energy, which could in turn materially adversely affect our stock price, business and financial results. In addition, while the Company will be entitled to up to $35.0 million in contingent consideration from the Joby Buyer upon the satisfaction of certain employee retention and financial performance targets, there can be no assurance that we will receive such contingent consideration. Any contingent consideration that we receive may be paid in cash or shares of Joby Aviation at the election of the Joby Buyer and, as a result, the value of any contingent consideration we receive may be subject to risks associated with Joby Aviation's business and common stock over which we have no control.

***Due to the effects of discontinued operations for the Passenger business, the Company's historical statements of operations included in prior periodic reports are not comparable to the Company's condensed consolidated statements of operations included in this Quarterly Report on Form 10-Q and will not be comparable to the Company's condensed consolidated statements of operations included in future periodic reports.***

The unaudited interim condensed consolidated statements of operations of the Company included in this Quarterly Report on Form 10-Q reflect the results of the Passenger business in discontinued operations for all periods presented. The Passenger business included all operations previously reported within the Passenger segment, as well as certain assets and

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

activities currently reported within unallocated corporate expenses and software development. The results of operations for the nine months ended September 31, 2025 and 2024 reflect the financial results of the Passenger business, including activity through August 29, 2025, as discontinued operations. The cash flows and comprehensive income of the Passenger business have not been separately presented and are included in the unaudited interim condensed consolidated statements of cash flows and unaudited interim condensed consolidated statements of comprehensive loss, respectively, for all periods presented. The Company's historical condensed consolidated statements of operations included in prior periodic reports do not reflect reporting of discontinued operations for the Passenger business. Accordingly, such historical condensed consolidated statements of operations included in prior periodic reports are not comparable to the condensed consolidated statements of operations included in this Quarterly Report on Form 10-Q or to the condensed consolidated statements of operations which will be included in future periodic reports of the Company. See Note 3 to the unaudited interim condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for additional information.

**Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities**

Not applicable.

**Item 3. Defaults Upon Senior Securities**

Not applicable.

**Item 4. Mine Safety Disclosures**

Not applicable.

**Item 5. Other information**

None.

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

**Item 6. Exhibits**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 2.1<sup>(1)</sup> | <u>[Equity Purchase Agreement, dated as of August 1, 2025, among Blade Air Mobility, Inc., Trinity Medical Intermediate II, Inc., Blade Urban Air Mobility, Inc., Joby Aviation, Inc. and Joby Aero, Inc.](https://www.sec.gov/Archives/edgar/data/1779128/000110465925073338/tm2522427d1_ex2-1.htm)</u> |
| 2.2<sup>(2)</sup> | <u>[Purchase and Sale Agreement, dated as of September 16, 2025, among Strata Critical, Inc., Keystone Perfusion Services, LLC, and other parties named therein, dated August 20, 2025](https://www.sec.gov/Archives/edgar/data/1779128/000177912825000114/cardio-stockpurchaseandsal.htm)</u> |
| 3.1<sup>(3)</sup> | <u>[Second Amended and Restated Certificate of Incorporation of Blade Air Mobility, Inc.](https://www.sec.gov/Archives/edgar/data/0001779128/000110465921065292/tm2115701d2_ex3-1.htm)</u> |
| 3.2<sup>(4)</sup> | <u>[Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of Blade Air Mobility, Inc.](https://www.sec.gov/Archives/edgar/data/1779128/000110465925085185/tm2524340d2_ex3-1.htm)</u> |
| 3.3<sup>(5)</sup> | <u>[Amended and Restated Bylaws of Strata Critical Medical, Inc.](https://www.sec.gov/Archives/edgar/data/1779128/000110465925085185/tm2524340d2_ex3-2.htm)</u> |
| 10.1<sup>(6)</sup> | <u>[Transition and Transaction Bonus Agreement, dated as of August 1, 2025, between Robert S. Wiesenthal and the Company](https://www.sec.gov/Archives/edgar/data/1779128/000110465925073338/tm2522427d1_ex10-1.htm)</u> +{ |
| 10.2<sup>(7)</sup> | <u>[Restrictive Covenant Agreement, dated as of August 29, 2025, between Strata Critical Medical, Inc. and Joby Aviation, Inc.](https://www.sec.gov/Archives/edgar/data/1779128/000110465925085185/tm2524340d2_ex10-1.htm)</u> { |
| 10.3<sup>(8)</sup> | <u>[Commercial Agreement, dated as of August 29, 2025 between Strata Critical Medical, Inc., Joby Aviation, Inc. and Joby Aero, Inc.](https://www.sec.gov/Archives/edgar/data/1779128/000110465925085185/tm2524340d2_ex10-2.htm)</u> |
| 10.4<sup>(9)</sup> | <u>[Form of Performance Stock Unit Agreement (EBITDA Earnout) Pursuant to the Strata Critical Medical, Inc. 2021 Omnibus Incentive Plan](https://www.sec.gov/Archives/edgar/data/1779128/000110465925085182/tm2524340d1_ex10-1.htm)</u> + |
| 10.5<sup>(10)</sup> | <u>[Form of Performance Stock Unit Agreement (2025 Co-CEO) Pursuant to the Strata Critical Medical, Inc.](https://www.sec.gov/Archives/edgar/data/1779128/000110465925085182/tm2524340d1_ex10-2.htm)</u> |
| 10.6<sup>(11)</sup> | <u>[Co-CEO Offer Letter with Melissa Tomkiel, dated August 28, 2025](https://www.sec.gov/Archives/edgar/data/1779128/000110465925085182/tm2524340d1_ex10-3.htm)</u>+ |
| 10.7<sup>(12)</sup> | <u>[Co-CEO Offer Letter with William Heyburn, dated August 28, 2025](https://www.sec.gov/Archives/edgar/data/1779128/000110465925085182/tm2524340d1_ex10-4.htm)</u>+ |
| 10.8\* | <u>[Strata Critical Medical, Inc. Amended and Restated Change in Control Severance Plan+](exhibit108-stratacriticalm.htm)</u> |
| 10.9\* | <u>[Strata Critical Medical, Inc. Flight Benefit Policy for Independent Directors, Co-Chief Executive Officers and Certain Other Officers+](exhibit109-strataflightben.htm)</u> |
| 31.1\*<sup>(13)</sup> | <u>[Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](srta-ex311xq32025.htm)</u> |
| 31.2\*<sup>(13)</sup> | <u>[Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](srta-ex312xq32025.htm)</u> |
| 32.1\*<sup>(13)</sup> | <u>[Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes- Oxley Act of 2002](srta-ex321xq32025.htm)</u> |
| 32.2\*<sup>(13)</sup> | <u>[Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes- Oxley Act of 2002](srta-ex322xq32025.htm)</u> |
| 101.INS\* | Interactive Data Files pursuant to Rule 405 of Regulation S-T formatted in Inline Extensible Business Reporting Language ("Inline XBRL") |
| 101.CAL\* | XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.SCH\* | XBRL Taxonomy Extension Schema Document |
| 101.DEF\* | XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB\* | XBRL Taxonomy Extension Labels Linkbase Document |
| 101.PRE\* | XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) |

---

_______________________________

\*Filed herewith

+ Denotes a management contract or compensatory arrangement.

⸶ Pursuant to Item 601(b) of Regulation S-K, certain exhibits, schedules and similar attachments have been omitted;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;exhibits, schedules and other attachments will be provided to the SEC upon request.

(1)Incorporated by reference to Exhibit 2.1 of our Form 8-K (file number 001-39046) filed on August 4, 2025.

(2)Incorporated by reference to Exhibit 2.1 of our Form 8-K (file number 001-39046) filed on September 16, 2025.

(3)Incorporated by reference to Exhibit 3.1 of our Form 8-K (file number 001-39046) filed on May 13, 2021.

(4)Incorporated by reference to Exhibit 3.1 of our Form 8-K (file number 001-39046) filed on August 29, 2025.

(5)Incorporated by reference to Exhibit 3.2 of our Form 8-K (file number 001-39046) filed on August 29, 2025.

(6)Incorporated by reference to Exhibit 10.1 of our Form 8-K (file number 001-39046) filed on August 4, 2025.

(7)Incorporated by reference to Exhibit 10.1 of our Form 8-K (file number 001-39046) filed on August 29, 2025.

(8)Incorporated by reference to Exhibit 10.2 of our Form 8-K (file number 001-39046) filed on August 29, 2025.

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

(9)Incorporated by reference to Exhibit 10.1 of our Form 8-K/A (file number 001-39046) filed on August 29, 2025.

(10)Incorporated by reference to Exhibit 10.2 of our Form 8-K/A (file number 001-39046) filed on August 29, 2025.

(11)Incorporated by reference to Exhibit 10.3 of our Form 8-K/A (file number 001-39046) filed on August 29, 2025.

(12)Incorporated by reference to Exhibit 10.4 of our Form 8-K/A (file number 001-39046) filed on August 29, 2025.

(13)This exhibit shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section. Such exhibit shall not be deemed incorporated into any filing under the Securities Act or the Exchange Act.

------

<u>[**Table of Contents**](#i944bdb891dfe41689e63162637d304aa_13)</u>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **STRATA CRITICAL MEDICAL, INC.** | **STRATA CRITICAL MEDICAL, INC.** |
| Date: November 10, 2025 | By: | /s/ Melissa Tomkiel |
|  | Name: | Melissa Tomkiel |
|  | Title: | Co-Chief Executive Officer<br>(Principal Executive Officer) |
| Date: November 10, 2025 | By: | /s/ William A. Heyburn |
|  | Name: | William A. Heyburn  |
|  | Title: | Co-Chief Executive Officer and Chief Financial Officer<br>(Principal Executive & Financial Officer) |
| Date: November 10, 2025 | By: | /s/ Amir M. Cohen |
|  | Name: | Amir M. Cohen |
|  | Title: | Chief Accounting Officer<br>(Principal Accounting Officer) |

---

## Exhibit 10.8

**Exhibit 10.8**

**STRATA CRITICAL MEDICAL, INC.<br>AMENDED AND RESTATED<br>CHANGE IN CONTROL SEVERANCE PLAN<br>AND<br>SUMMARY PLAN DESCRIPTION**

**ORIGINALLY APPROVED BY THE BOARD OF DIRECTORS: December 20, 2021<br>AMENDED AND RESTATED BY THE BOARD OF DIRECTORS: August 29, 2025**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.<u>Introduction</u>. The purpose of this Strata Critical Medical, Inc. Amended and Restated Change in Control Severance Plan (the "<u>Plan</u>") is to provide assurances of specified severance benefits to eligible executives of the Company whose employment is terminated by the Company or a successor under certain circumstances. This Plan is an "employee welfare benefit plan," as defined in Section 3(1) of ERISA (as defined below). This Plan shall supersede any individual agreement between the Company and any Covered Employee (as defined below) and any other plan, policy or practice, whether written or unwritten, maintained by the Company with respect to a Covered Employee, in each case to the extent that such agreement, plan, policy or practice provides for equity acceleration or severance benefits upon the Covered Employee's separation from the Company. This document constitutes both the written instrument under which the Plan is maintained and the required summary plan description for the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.<u>Definitions</u>. For purposes of the Plan, the terms below are defined as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1."<u>Administrator</u>" means the Board or Compensation Committee prior to a Change in Control; or, after a Change in Control, one or more members of the successor Board or Compensation Committee or other persons designated by the Company's Board or Compensation Committee prior to such Change in Control.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2."<u>Board</u>" means the Board of Directors of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3."<u>Cause</u>" means, as to any Covered Employee, the Covered Employee's (i) willful neglect in the performance of the Covered Employee's duties for the Company (or any parent or subsidiary of the Company) or willful or repeated failure or refusal to perform such duties; (ii) engagement in conduct in connection with the Covered Employee's employment or service with the Company (or any parent or subsidiary of the Company), which results in, or could reasonably be expected to result in, material harm to the business or reputation of the Company (or any parent or subsidiary of the Company); (iii) conviction of, or plea of guilty or no contest to (A) any felony or (B) any other crime that results in, or could reasonably be expected to result in, material harm to the business or reputation of the Company (or any parent or subsidiary of the Company); (iv) material violation of the written policies of the Company (or any parent or subsidiary of the Company), including, but not limited to, those relating to sexual harassment or the disclosure or misuse of confidential information, or those set forth in the manuals or statements of policy of the Company (or any parent or subsidiary of the Company); (v) fraud or misappropriation, embezzlement, or misuse of funds or property belonging to the Company (or any parent or subsidiary of the Company); or (vi) act of personal dishonesty that involves personal profit in connection with the Covered Employee's employment or service to Company (or any parent or subsidiary of the Company); <u>provided</u>, in any case, that a the Covered Employee's resignation after an event that would be grounds for a termination for Cause will be treated as a termination for Cause hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4."<u>Change in Control</u>" has the meaning ascribed to such term in the Stock Plan on the Effective Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5."<u>Change in Control Period</u>" means the time period beginning three months prior to the date on which a Change in Control becomes effective and ending on the first anniversary of the effective date of such Change in Control.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.6."<u>Co-CEO</u>" means either of the Co-Chief Executive Officers of the Company, or, if at any time there is only one Chief Executive Officer of the Company, such Chief Executive Officer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.7."<u>COBRA</u>" means the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.8."<u>Code</u>" means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.9."<u>Company</u>" means Strata Critical Medical, Inc. and any successor.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.10."<u>Compensation Committee</u>" means the Compensation Committee of the Board.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.11."<u>Covered Employee</u>" means an employee of the Company who (i) is a Co-CEO, a Group A Participant or a Group B Participant and (ii) has timely and properly executed and delivered a Participation Agreement to the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.12."<u>Covered Termination</u>" means (i) a Co-CEO's termination of employment by the Company (or any parent or subsidiary of the Company) without Cause or as a result a Co-CEO's resignation for Good Reason at any time or (ii) with respect to any other Covered Employee, such Covered Employee's termination of employment by the Company (or any parent or subsidiary of the Company) without Cause at any time or, solely if such resignation occurs during the Change in Control Protection Period, such Covered Employee's resignation for Good Reason; <u>provided</u>, that, in all cases, such termination is not due to the Covered Employee's death or permanent disability.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.13."<u>Effective Date</u>" means the effective date of this Plan, which is [December 20, 2021], the date on which the Plan was approved by the Board.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.14."<u>ERISA</u>" means the Employee Retirement Income Security Act of 1974, as amended.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.15."<u>Good Reason</u>" means a Covered Employee's resignation within 30 days following the expiration of the cure period described below following the occurrence of one or more of the following, without such Covered Employee's express written consent: (i) a material reduction of the Covered Employee's duties, or responsibilities, <u>provided</u>, that a change in job position (including a change in title) shall not be deemed a "material reduction" in and of itself unless the Covered Employee's new duties are materially reduced from the Covered Employee's prior duties; (ii) a material reduction in the Covered Employee's base salary (for clarity, a reduction by 10% or more will be considered a material reduction); <u>provided</u>, that an across the board base salary reduction to all senior executives of the Company will not be grounds for Good Reason; (iii) a material change in the geographic location of the Covered Employee's primary work facility or location; <u>provided</u>, that a relocation of less than 30 miles from the Covered Employee's then present location will not be considered a material change in geographic location; or (iv) with respect to a Co-CEO only, a change in reporting such that the Co-CEO does not report solely to the Lead Independent Director (if any) and the Board. The Covered Employee will not resign for Good Reason without first providing the Company with written notice of the acts or omissions constituting the grounds for Good Reason within 90 days of the initial existence of the grounds for Good Reason and a cure period of not less than 30 days following the date of such notice.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.16."<u>Group A Participant</u>" means a Covered Employee serving as the Company's President or Chief Financial Officer (other than any such Covered Employee also serving as a Co-CEO).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.17."<u>Group B Participant</u>" means a Covered Employee (other than a Co-CEO and a Group A Participant) who is an "officer" of the Company as defined by Rule 16a-1(f) under the Securities Exchange Act of 1934 as amended, or any successor thereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.18."<u>Participation Agreement</u>" means an agreement between a Covered Employee and the Company in substantially the form of <u>Appendix A</u> attached hereto, and which may include such other terms as the Administrator deems necessary or advisable in the administration of the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.19."<u>Severance Benefits</u>" means the compensation and other benefits the Covered Employee will be provided pursuant to either Section 4.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.20."<u>Stock Plan</u>" means the Company's 2021 Omnibus Incentive Plan, as amended or amended and restated from time to time, or any successor thereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.21."<u>Termination Date</u>" means the Covered Employee's last day of employment with the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.<u>Eligibility for Severance Benefits</u>. An individual is eligible for severance benefits under the Plan, in the amounts set forth in Section 4, only if such individual is a Covered Employee on the date such individual experiences a Covered Termination.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.<u>Severance Benefits</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1.<u>Covered Termination Outside the Change in Control Period</u>. If, at any time outside of the Change in Control Period, a Covered Employee experience a Covered Termination, then, subject to the Covered Employee's compliance with Section 5, the Covered Employee shall receive the following Severance Benefits from the Company (the "<u>Standard Severance Benefits</u>"):

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1.1<u>Cash Severance Benefits</u>. The Covered Employee shall receive cash severance in an amount equal to the Covered Employee's base salary (as in effect immediately prior to any reduction giving rise to Good Reason, if applicable) for the applicable number of months set forth in the Covered Employee's Participation Agreement (the "<u>Standard Severance Period</u>"). The cash amount shall be paid, less applicable tax withholdings, in a single lump sum on the first payroll date following the effective date of the Release (the "<u>Payment Date</u>").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1.2<u>COBRA Premiums</u>. Provided the Covered Employee is eligible for and timely makes the necessary elections for continuation coverage pursuant to COBRA the Company shall pay the applicable premiums (inclusive of premiums for the Covered Employee's dependents) for such coverage following the date of the Covered Employee's Covered Termination for the Standard Severance Period (such period of months, the "<u>Standard COBRA Payment Period</u>") (but in no event after such time as the Covered Employee is eligible for coverage under a health, dental or vision insurance plan of a subsequent employer or as the Covered Employee and the Covered Employee's dependents are no longer eligible for COBRA coverage). The Covered Employee shall notify the Company immediately if the Covered Employee becomes covered by a health, dental, or vision insurance plan of a subsequent employer or if the Covered Employee's dependents are no longer eligible for COBRA coverage. Notwithstanding the foregoing, if at any time the Company determines, in its sole discretion, that it cannot provide the COBRA premium benefits without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then in lieu of paying COBRA premiums on the Covered Employee's behalf, the Company will instead pay such Covered Employee on the last day of each remaining month of the Standard COBRA Payment Period a fully taxable cash payment equal to the COBRA premium for that month, subject to applicable tax withholding (such amount, the "<u>Special Severance Payment</u>"), such Special Severance Payment to be made without regard to the Covered Employee's election of COBRA coverage or payment of COBRA premiums and without regard to such Covered Employee's continued eligibility for COBRA coverage during the Standard COBRA Payment Period. Such Special Severance Payment shall end upon expiration of the Standard COBRA Payment Period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2.<u>Covered Termination During the Change in Control Period</u>. If, at any time during the Change in Control Period, a Covered Employee experiences a Covered Termination, then, subject to the Covered Employee's compliance with Section 5, the Covered Employee shall receive the following Severance Benefits from the Company (the "<u>CIC Severance Benefits</u>"):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2.1<u>Cash Severance Benefits</u>. The Covered Employee shall receive cash severance in an amount equal to the Covered Employee's base salary (as in effect immediately prior to any reduction giving rise to Good Reason, if applicable) for the applicable number of months set forth in the Covered Employee's Participation Agreement (the "<u>CIC Severance Period</u>"). The cash amount shall be paid, less applicable tax withholdings, in a single lump sum on the Payment Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2.2<u>Prorated Target Annual Bonus Entitlemen</u>t. The Covered Employee will additionally be entitled to a portion of such Covered Employee's target annual bonus (if any), as established by the Board for the year in which the Covered Termination occurs. Such payment shall be in an amount equal to the product of (i) the Covered Employee's target annual bonus (if any) and (ii) a fraction, the numerator of which is the number of days the Covered Employee was employed during the fiscal year in which the Termination Date occurs (inclusive of such date), and the denominator of which is the total number of days in such fiscal year. The cash amount shall be paid, less applicable tax withholdings, in a single lump sum on the Payment Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2.3<u>COBRA Premiums</u>. Provided the Covered Employee is eligible for and timely makes the necessary elections for continuation coverage pursuant to COBRA the Company shall pay the applicable premiums (inclusive of premiums for the Covered Employee's dependents) for such coverage following the date of the Covered Employee's Covered Termination for up to the CIC Severance Period (such period of months, the "<u>CIC COBRA Payment Period</u>") (but in no event after such time as the Covered Employee is eligible for coverage under a health, dental or vision insurance plan of a subsequent employer or as the Covered Employee and the Covered Employee's dependents are no longer eligible for COBRA coverage). The Covered Employee shall notify the Company immediately if the Covered Employee becomes covered by a health, dental, or vision insurance plan of a subsequent employer or if the Covered Employee's dependents are no longer eligible for COBRA coverage. Notwithstanding the foregoing, if at any time the Company determines, in its sole discretion, that it cannot provide the COBRA premium benefits without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then in lieu of paying COBRA premiums on the Covered Employee's behalf, the Company will instead pay such Covered Employee on the last day of each remaining month of the CIC COBRA Payment Period a Special Severance Payment to be made without regard to the Covered Employee's election of COBRA coverage or payment of COBRA premiums and without regard to such Covered Employee's continued eligibility for COBRA coverage during the CIC COBRA Payment Period. Such Special Severance Payment shall end upon expiration of the CIC COBRA Payment Period.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2.4<u>Equity Vesting</u>. Each of the Covered Employee's then-outstanding equity awards granted pursuant to the Stock Plan and any prior equity incentive plan of the Company that are subject to a time-based vesting schedule shall accelerate and become vested and exercisable as to 100% of the unvested shares subject to the equity award, except any award granted after the Effective Date that explicitly overrides this provision in writing. Subject to Section 5, the accelerated vesting described in this paragraph shall be effective as of the Termination Date. Notwithstanding anything herein to the contrary, nothing in the Plan shall limit the Company's ability to accelerate vesting and/or exercisability of outstanding equity awards pursuant to the terms of the Stock Plan or any prior equity incentive plan of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.<u>Conditions to Receipt of Severance</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1.<u>Release Agreement</u>. As a condition to receiving the Severance Benefits, a Covered Employee must sign a release of all claims in favor of the Company and its subsidiaries and affiliates (the "<u>Release</u>") in such form as may be provided by the Company. The Release must become effective in accordance with its terms, which must occur in no event more than 60 days following the date of the applicable Covered Termination. In no event shall payment of any benefits under the Plan be made prior to a Covered Employee's Termination Date or prior to the effective date of the Release. If the Company determines that any payments or benefits provided under the Plan constitute "deferred compensation" under Section 409A, and the Covered Employee's Termination Date occurs at a time during the calendar year when the Release could become effective in the calendar year following the calendar year in which the Covered Employee's "separation from service" within the meaning of Section 409A of the Code and the final regulations and any guidance promulgated thereunder ("<u>Section 409A</u>") occurs, then regardless of when the Release is returned to the Company and becomes effective, the Release will not be deemed effective any earlier than the latest permitted effective date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2.<u>Other Requirements</u>. A Covered Employee's receipt of Severance Benefits pursuant to Section 4 will be subject to such Covered Employee continued material compliance with the terms of the Release, the Participation Agreement, and any restrictive covenants agreement and any other material agreement between the Covered Employee and the Company. Severance Benefits under this Plan shall terminate immediately for a Covered Employee if such Covered Employee is in material violation, at any time, of any legal or contractual obligation owed to the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3.<u>Section 280G</u>. Any provision of the Plan to the contrary notwithstanding, if any payment or benefit a Covered Employee would receive from the Company and its subsidiaries or an acquiror pursuant to the Plan or otherwise (a "<u>Payment</u>") would (i) constitute a "parachute payment" within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the "<u>Excise Tax</u>"), then such Payment will be equal to the Higher Amount (defined below). The "<u>Higher Amount</u>" will be either (x) the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount, after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Covered Employee's receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting "parachute payments" within the meaning of Section 280G of the Code is necessary so that the Payment equals the Higher Amount, reduction will occur in the manner that results in the greatest economic benefit for a Covered Employee and, to the extent applicable, complies with Section 409A. In no event will the Company, any subsidiary or any stockholder be liable to any Covered Employee for any amounts not paid as a result of the operation of this Section 5.3. The Company will use commercially reasonable efforts to cause the accounting or law firm engaged to make the determinations hereunder to provide its calculations, together with detailed supporting documentation, to a Covered Employee and the Company within 15 calendar days after the date on which such Covered Employee's right to a Payment is triggered (if requested at that time by such Covered Employee or the Company) or such other time as requested by such Covered Employee or the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.<u>Non-Duplication of Benefits</u>. Notwithstanding any other provision in the Plan to the contrary, the Severance Benefits provided to a Covered Employee are intended to be and are exclusive and in lieu of any other change in control severance benefits or payments to which such Covered Employee may otherwise be entitled, either at law, tort, or contract, in equity, or under the Plan, in the event of any termination of such Covered Employee's employment. The Covered Employee will be entitled to no change in control severance benefits or payments upon a termination of employment that constitutes a Covered Termination other than those benefits expressly set forth herein and those benefits required to be provided by applicable law or as negotiated in accordance with applicable law (including any severance benefits that may be included in a severance agreement, employment agreement or similar contract between the Company or a subsidiary of the Company and the Covered Employee). Notwithstanding the foregoing, if a Covered Employee is entitled to any benefits other than the benefits under the Plan by operation of applicable law or as negotiated in accordance with applicable law, such Covered Employee's benefits under the Plan shall be provided only to the extent more favorable than such other arrangement. The Administrator, in its sole discretion, shall have the authority to reduce or otherwise adjust a Covered Employee's benefits under the Plan, in whole or in part, by any other severance benefits, pay and benefits in lieu of notice, or other similar benefits payable to such Covered Employee under the Plan that become payable in connection with the

------

Covered Employee's termination of employment pursuant to (i) any applicable legal requirement, including the Worker Adjustment and Retraining Notification Act (the "<u>WARN Act</u>"), the California Plant Closing Act or any other similar state law, or (ii) any policy or practice of the Company providing for the Covered Employee to remain on payroll for a limited period of time after being given notice of termination. The benefits provided under the Plan are intended to satisfy, in whole or in part, any and all statutory obligations of the Company that may arise out of a Covered Employee's termination of employment, and the Administrator shall so construe and implement the terms of the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.<u>Clawback; Recovery</u>. All payments and severance benefits provided under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company's securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. In addition, the Administrator may impose such other clawback, recovery or recoupment provisions as the Administrator determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of common stock of the Company or other cash or property upon the occurrence of a termination of employment for Cause. No recovery of compensation under such a clawback policy will be an event giving rise to a right to resign for Good Reason, constructive termination, or any similar term under any plan of or agreement with the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.<u>Section 409A</u>. Notwithstanding anything to the contrary in the Plan, to the extent required by Section 409A, no severance payments or benefits will become payable until the Covered Employee has a "separation from service" within the meaning of Section 409A. Further, if some or all of the Covered Employee's Severance Benefits are subject to Section 409A and such Covered Employee is a "specified employee" within the meaning of Section 409A at the time of such Covered Employee's separation from service (other than due to death), then such Severance Benefits otherwise due to such Covered Employee on or within the six-month period following such Covered Employee's separation from service will accrue during such six-month period and will become payable in a lump sum payment (less applicable withholding taxes) on the date six months and one day following the date of the Covered Employee's separation from service if necessary to avoid adverse taxation under Section 409A. All subsequent payments, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit. Notwithstanding anything herein to the contrary, if the Covered Employee dies following such Covered Employee's separation from service but prior to the six-month anniversary of such Covered Employee's date of separation, then any payments delayed in accordance with this paragraph will be payable in a lump sum (less applicable withholding taxes) to the Covered Employee's estate as soon as administratively practicable after the date of such Covered Employee's death and all other benefits will be payable in accordance with the payment schedule applicable to each payment or benefit. Each payment and benefit payable under the Plan is intended to constitute a separate payment for purposes of Section 409A. It is the intent of this Plan to comply with or be exempt from the requirements of Section 409A so that none of the severance payments and benefits to be provided hereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted to so comply. Notwithstanding the foregoing, the Company makes no representations that the payments and benefits provided under the Plan comply with Section 409A, and in no event shall the Company or any of its representatives be liable for all or any portion of any taxes, penalties, interest, or other expenses that may be incurred by the Covered Employee on account of non-compliance with Section 409A.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.<u>Withholding</u>. The Company will withhold from any Severance Benefits all federal, state, local and other taxes required to be withheld therefrom and any other required payroll deductions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.<u>Administration</u>. The Plan will be administered and interpreted by the Administrator (in the Administrator's sole discretion). The Administrator is the "named fiduciary" of the Plan for purposes of ERISA and will be subject to the fiduciary standards of ERISA when acting in such capacity. Any decision made or other action taken by the Administrator with respect to the Plan, and any interpretation by the Administrator of any term or condition of the Plan, or any related document, will be conclusive and binding on all persons and be given the maximum possible deference allowed by law. Any decision made or other action taken by the Administrator with respect to the Plan, and any interpretation by the Administrator of any term or condition of the Plan, or any related document that (i) does not affect the benefits payable under the Plan shall not be subject to review unless found to be arbitrary and capricious or (ii) does affect the benefits payable under the Plan shall not be subject to review unless found to be unreasonable or not to have been made in good faith.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.<u>Term; Amendment or Termination</u>. The Plan may not be amended, modified, suspended or terminated except with the express written consent of each Covered Employee who would be adversely affected by any such amendment, modification, suspension or termination. The Plan automatically will terminate on the third anniversary of the Effective Date, unless otherwise amended or extended at the discretion of the Administrator; <u>provided</u>, that in the event a Change in Control has occurred on or prior to such anniversary date, the Plan shall terminate on the date on which all rights and obligations hereunder have been fully satisfied or forfeited.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.<u>Claims Procedure</u>. Claims for benefits under the Plan shall be administered in accordance with Section 503 of ERISA and the Department of Labor Regulations thereunder. Any employee or other person who believes they are entitled to any payment under the Plan (a "<u>claimant</u>") may submit a claim in writing to the Administrator within 90 days of the earlier of (i) the date the claimant learned the amount of such claimant's severance benefits under the Plan or (ii) the date the claimant learned that they will not be entitled to any benefits

------

under the Plan. In determining claims for benefits, the Administrator or its delegate has the authority to interpret the Plan, to resolve ambiguities, to make factual determinations, and to resolve questions relating to eligibility for and amount of benefits. If the claim is denied (in full or in part), the claimant will be provided a written notice explaining the specific reasons for the denial and referring to the provisions of the Plan on which the denial is based. The notice will also describe any additional information or material that the Administrator needs to complete the review and an explanation of why such information or material is necessary and the Plan's procedures for appealing the denial (including a statement of the applicant's right to bring a civil action under Section 502(a) of ERISA following a denial on review of the claim, as described below). The denial notice will be provided within 90 days after the claim is received. If special circumstances require an extension of time (up to 90 days), written notice of the extension will be given to the claimant (or representative) within the initial 90-day period. This notice of extension will indicate the special circumstances requiring the extension of time and the date by which the Administrator expects to render its decision on the claim. If the extension is provided due to a claimant's failure to provide sufficient information, the time frame for rendering the decision will be tolled from the date the notification is sent to the claimant about the failure to the date on which the claimant responds to the request for additional information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.<u>Appeal Procedure</u>. If the claimant's claim is denied, the claimant (or such claimant's authorized representative) may apply in writing to an appeals official appointed by the Administrator (which may be a person, committee or other entity) for a review of the decision denying the claim. Review must be requested within 60 days following the date the claimant received the written notice of a claim denial or else the claimant will lose the right to such review. A request for review must set forth all the grounds on which such request is based, all facts in support of the request, and any other matters that the claimant feels are pertinent. In connection with the request for review, the claimant (or representative) has the right to review and obtain copies of all documents and other information relevant to the claim, upon request and at no charge, and to submit written comments, documents, records and other information relating to such claimant's claim. The review shall take into account all comments, documents, records and other information submitted by the claimant (or representative) relating to the claim, without regard to whether such information was submitted or considered in the initial benefit determination. The appeals official will provide written notice of its decision on review within 60 days after it receives a review request. If special circumstances require an extension of time (up to 60 days), written notice of the extension will be given to the claimant (or representative) within the initial 60-day period. This notice of extension will indicate the special circumstances requiring the extension of time and the date by which the appeals official expects to render its decision. If the extension is provided due to a claimant's failure to provide sufficient information, the time frame for rendering the decision on review is tolled from the date the notification is sent to the claimant about the failure to the date on which the claimant responds to the request for additional information. If the claim is denied (in full or in part) upon review, the claimant will be provided a written notice explaining the specific reasons for the denial and referring to the provisions of the Plan on which the denial is based. The notice shall also include a statement that the claimant will be provided, upon request and free of charge, reasonable access to, and copies of, all documents and other information relevant to the claim and a statement regarding the claimant's right to bring an action under Section 502(a) of ERISA.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.<u>Arbitration</u>. No arbitration proceeding shall be brought to recover benefits under the Plan until the claims procedures described in Sections 12 and 13 have been exhausted and the Plan benefits requested have been denied in whole or in part. Notwithstanding any other provision of the Plan, to ensure the timely and economical resolution of disputes, all disputes, claims, or causes of action arising from or relating to the enforcement, breach, performance or interpretation of this Plan will be resolved to the fullest extent permitted by law by final, binding and confidential arbitration, by a single arbitrator, in New York City, New York, conducted by JAMS, Inc. ("<u>JAMS</u>") under the then-applicable JAMS rules (available at the following web address: https://www.jamsadr.com/rules-employment). By agreeing to this arbitration procedure, each Covered Employee and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding. Covered Employees will have the right to be represented by legal counsel at any arbitration proceeding. In addition, all claims, disputes, or causes of action under this section, whether by a Covered Employee or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity. The arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative or class proceeding. To the extent that the preceding sentences regarding class claims or proceedings are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law rather than by arbitration. The arbitrator shall: (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (b) issue a written arbitration decision, to include the arbitrator's essential findings and conclusions and a statement of the award. The arbitrator shall be authorized to award any or all remedies that a Covered Employee or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS' arbitration fees in excess of the amount of court fees that would be required of a Covered Employee if the dispute were decided in a court of law. Nothing in this paragraph is intended to prevent either a Covered Employee or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction. Any arbitration must be commenced within one year after the Covered Employee's receipt of notification that their appeal was denied. The foregoing provisions shall apply to the extent consistent with and permitted by ERISA.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.<u>Source of Payments</u>. All severance benefits will be paid in cash from the general funds of the Company; no separate fund will be established under the Plan, and the Plan will have no assets. No right of any person to receive any payment under the Plan will be any greater than the right of any other general unsecured creditor of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.<u>Inalienability</u>. In no event may any current or former employee of the Company or any of its subsidiaries or affiliates sell, transfer, anticipate, assign or otherwise dispose of any right or interest under the Plan. At no time will any such right or interest be subject to the claims of creditors nor liable to attachment, execution or other legal process.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17.<u>No Enlargement of Employment Rights</u>. Neither the establishment nor maintenance of the Plan, any amendment of the Plan, nor the making of any benefit payment hereunder, will be construed to confer upon any individual any right to be continued as an employee of the Company. The Company expressly reserves the right to discharge any of its employees at any time, with or without cause. However, as described in the Plan, a Covered Employee may be entitled to benefits under the Plan depending upon the circumstances of such Covered Employee's termination of employment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.<u>Successors</u>. Any successor to the Company of all or substantially all of the Company's business or assets (whether direct or indirect and whether by purchase, merger, consolidation, liquidation or otherwise) will assume the obligations under the Plan and agree expressly to perform the obligations under the Plan in the same manner and to the same extent as the Company would be required to perform such obligations in the absence of a succession. For all purposes under the Plan, the term "Company" will include any successor to the Company's business or assets which become bound by the terms of the Plan by operation of law, or otherwise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19.<u>Applicable Law</u>. The provisions of the Plan will be construed, administered and enforced in accordance with ERISA and, to the extent applicable, the internal substantive laws of the State of Delaware (except its conflicts of law provisions).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20.<u>Severability</u>. If any provision of the Plan is held invalid or unenforceable, its invalidity or unenforceability will not affect any other provision of the Plan, and the Plan will be construed and enforced as if such provision had not been included.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21.<u>Headings</u>. Headings in this Plan document are for purposes of reference only and will not limit or otherwise affect the meaning hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22.<u>Additional Information</u>.

Plan Name:&nbsp;&nbsp;&nbsp;&nbsp;Strata Critical Medical, Inc. Amended and Restated Change in Control Severance Plan

Plan Sponsor:&nbsp;&nbsp;&nbsp;&nbsp;Strata Critical Medical, Inc.

Plan Year:&nbsp;&nbsp;&nbsp;&nbsp;Fiscal year ending December 31

Plan Administrator:&nbsp;&nbsp;&nbsp;&nbsp;Strata Critical Medical, Inc.

&nbsp;&nbsp;&nbsp;&nbsp;Attention: Administrator of the Strata Critical Medical, Inc. Amended and Restated Change in Control Severance Plan

Agent for Service of&nbsp;&nbsp;&nbsp;&nbsp;Strata Critical Medical, Inc.

Legal Process:&nbsp;&nbsp;&nbsp;&nbsp;Attention: Administrator of the Strata Critical Medical, Inc. Amended and Restated Change in Control Severance Plan

&nbsp;&nbsp;&nbsp;&nbsp;Service of process may also be made upon the Administrator.

Type of Plan: &nbsp;&nbsp;&nbsp;&nbsp;Severance Plan/Employee Welfare Benefit Plan

Plan Costs: &nbsp;&nbsp;&nbsp;&nbsp;The cost of the Plan is paid by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23.<u>Statement of ERISA Rights</u>.

As a Covered Employee under the Plan, you have certain rights and protections under ERISA:

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)You may examine (without charge) all Plan documents, including any amendments and copies of all documents filed with the U.S. Department of Labor. These documents are available for your review in the office of the Company's General Counsel.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)You may obtain copies of all Plan documents and other Plan information upon written request to the Administrator. A reasonable charge may be made for such copies.

In addition to creating rights for Covered Employees, ERISA imposes duties upon the people who are responsible for the operation of the Plan. The people who operate the Plan (called "<u>fiduciaries</u>") have a duty to do so prudently and in the interests of you and the other Covered Employees. No one, including the Company or any other person, may fire you or otherwise discriminate against you in any way to prevent you from obtaining a benefit under the Plan or exercising your rights under ERISA. If your claim for a severance benefit is denied, in whole or in part, you have a right to know why it was denied, to obtain copies of documents relating to the decision without charge, and to appeal any denial, all within certain time schedules. The claim review procedure is explained in Sections 12 and 13, above.

Under ERISA, there are steps you can take to enforce the above rights. For instance, if you request a copy of Plan documents and do not receive them within 30 days, you may file suit in a federal court. In such a case, the court may require the Administrator to provide the materials and to pay you up to $110 a day until you receive the materials, unless the materials were not sent because of reasons beyond the control of the Administrator. If you have a claim which is denied or ignored, in whole or in part, you may file suit in a federal court. If it should happen that you are discriminated against for asserting your rights, you may seek assistance from the U.S. Department of Labor, or you may file suit in a federal court. The court will decide who should pay court costs and legal fees. If you are successful, the court may order the person you have sued to pay these costs and fees. If you lose, the court may order you to pay these costs and fees, for example, if it finds your claim is frivolous.

If you have any questions regarding the Plan, please contact the Administrator. If you have any questions about this statement or about your rights under ERISA, you may contact the nearest office of the Employee Benefits Security Administration, U.S. Department of Labor, listed in your telephone directory, or the Division of Technical Assistance and Inquiries, Employee Benefits Security Administration, U.S. Department of Labor, 200 Constitution Avenue, N.W., Washington, D.C. 20210. You may also obtain certain publications about your rights and responsibilities under ERISA by calling the publications hotline of the Employee Benefits Security Administration at 1-866-444-3272.

------

APPENDIX A

**STRATA CRITICAL MEDICAL, INC.<br>AMENDED AND RESTATED<br>CHANGE IN CONTROL SEVERANCE PLAN**

**Participation Agreement**

Strata Critical Medical, Inc. (the "<u>Company</u>") is pleased to inform you, [name], that you have been selected to participate in the Company's Amended and Restated Change in Control Severance Plan (the "<u>Plan</u>") as a Covered Employee. A copy of the Plan was delivered to you with this Participation Agreement. Your participation in the Plan is subject to all of the terms and conditions of the Plan. The capitalized terms used but not defined herein will have the meanings ascribed to them in the Plan.

In order to become a Covered Employee under the Plan, you must complete and sign this Participation Agreement and return it to [name] no later than [date].

The Plan describes in detail certain circumstances under which you may become eligible for Severance Benefits and the amount of those benefits. As described more fully in the Plan, you may become eligible for certain Severance Benefits if you experience a Covered Termination.

If you become eligible for Standard Severance Benefits under Section 4.1 of the Plan, then subject to the terms and conditions of the Plan, you will receive:

**Co-CEO Version:**

Cash Severance Benefits&nbsp;&nbsp;&nbsp;&nbsp;18 months

COBRA Premiums&nbsp;&nbsp;&nbsp;&nbsp;18 months

**Group A Participant Version:**

Cash Severance Benefits&nbsp;&nbsp;&nbsp;&nbsp;12 months

COBRA Premiums&nbsp;&nbsp;&nbsp;&nbsp;12 months

**Group B Participant Version:**

Cash Severance Benefits&nbsp;&nbsp;&nbsp;&nbsp;9 months

COBRA Premiums&nbsp;&nbsp;&nbsp;&nbsp;9 months

If you become eligible for CIC Severance Benefits under Section 4.2 of the Plan, then subject to the terms and conditions of the Plan, you will receive:

**Co-CEO Version:**

Cash Severance Benefits&nbsp;&nbsp;&nbsp;&nbsp;24 months

COBRA Premiums&nbsp;&nbsp;&nbsp;&nbsp;24 months

**Group A Participant Version:**

Cash Severance Benefits&nbsp;&nbsp;&nbsp;&nbsp;12 months

COBRA Premiums&nbsp;&nbsp;&nbsp;&nbsp;12 months

**Group B Participant Version:** 

Cash Severance Benefits&nbsp;&nbsp;&nbsp;&nbsp;9 months

COBRA Premiums&nbsp;&nbsp;&nbsp;&nbsp;9 months

------

In order to receive any Severance Benefits for which you otherwise become eligible under the Plan, you must sign and deliver to the Company the Release, which must have become effective and irrevocable, and otherwise comply with the requirements under Section 5 of the Plan.

In accordance with Section 6 of the Plan, the benefits, if any, provided under the Plan are intended to be the exclusive benefits for you related to your termination of employment in connection with a change in control of the Company and will supersede and replace any change in control severance benefits to which you otherwise would eligible to participate in any other Company change in control severance policy, plan, agreement or other arrangement (whether or not subject to ERISA).

By your signature below, you and the Company agree that your participation in the Plan is governed by this Participation Agreement and the provisions of the Plan. Your signature below confirms that: (i) you have received a copy of the Plan; (ii) you have carefully read this Participation Agreement and the Plan and you acknowledge and agree to its terms, including, but not limited to, Section 6 of the Plan; (iii) you agree that this Participation Agreement and the provisions of the Plan supersede any individual agreement between you and the Company and any other plan, policy or practice, whether written or unwritten, maintained by the Company with respect to equity acceleration or severance benefits upon your separation from the Company; and (iv) decisions and determinations by the Administrator under the Plan will be final and binding on you and your successors.

[SIGNATURE PAGE TO STRATA CRITICAL MEDICAL, INC.<br>AMENDED AND RESTATED CHANGE IN CONTROL SEVERANCE PLAN]

------

**STRATA CRITICAL MEDICAL, INC. &nbsp;&nbsp;&nbsp;&nbsp;COVERED EMPLOYEE**

<u>&nbsp;&nbsp;&nbsp;&nbsp;</u>&nbsp;&nbsp;&nbsp;&nbsp;<u>&nbsp;&nbsp;&nbsp;&nbsp;</u>

&nbsp;&nbsp;&nbsp;&nbsp;Signature&nbsp;&nbsp;&nbsp;&nbsp;Signature

Name;&nbsp;&nbsp;&nbsp;&nbsp;<u>&nbsp;&nbsp;&nbsp;&nbsp;</u>&nbsp;&nbsp;&nbsp;&nbsp;Name:&nbsp;&nbsp;&nbsp;&nbsp;<u>&nbsp;&nbsp;&nbsp;&nbsp;</u>

Title:&nbsp;&nbsp;&nbsp;&nbsp;<u>&nbsp;&nbsp;&nbsp;&nbsp;</u>&nbsp;&nbsp;&nbsp;&nbsp;Title:&nbsp;&nbsp;&nbsp;&nbsp;<u>&nbsp;&nbsp;&nbsp;&nbsp;</u>

Date:&nbsp;&nbsp;&nbsp;&nbsp;<u>&nbsp;&nbsp;&nbsp;&nbsp;</u>&nbsp;&nbsp;&nbsp;&nbsp;Date:&nbsp;&nbsp;&nbsp;&nbsp;<u>&nbsp;&nbsp;&nbsp;&nbsp;</u>

Attachment: Strata Critical Medical, Inc. Amended and Restated Change in Control Severance Plan

[SIGNATURE PAGE TO STRATA CRITICAL MEDICAL, INC.<br>AMENDED AND RESTATED CHANGE IN CONTROL SEVERANCE PLAN]

## Exhibit 10.9

**Exhibit 10.9**

**STRATA CRITICAL MEDICAL, INC.**

**FLIGHT BENEFIT POLICY FOR INDEPENDENT DIRECTORS, CO-CHIEF EXECUTIVE OFFICERS AND CERTAIN OTHER OFFICERS**

Strata Critical Medical, Inc. (the "***Company***") recognizes that certain Independent Members of the Board of Directors (the "***Directors***"), the co-Chief Executive Officers (the "***CEOs***") and certain other members of management (the "***Other Officers***") of the Company may want to utilize Company services for personal travel. The Company believes that personal use of Company services helps to strengthen the Directors', CEOs' and Other Officers' connection to the Company and strengthens our relationships. The purpose of this Flight Benefit Policy (the "***Policy***") for the Directors, the CEOs and Other Officers is to provide appropriate guidelines to the Directors, the CEOs and the Other Officers for utilizing Company services for personal travel.

Subject to the Policy, the Directors, the CEOs and the Other Officers can arrange personal travel on Company flights at no charge for up to the following number of flight hours on the Company's network of owned, dedicated and contracted aircraft during each calendar year (the "***Annual Flight Allowance***"): 10 flight hours for the Directors; 20 flight hours for the CEOs; and up to 20 flight hours to be allocated to Other Officers at the discretion of the CEOs. Flight hours flown will apply to the Annual Flight Allowance as follows: 0.7 of a flight hour for each hour flown on a turboprop aircraft, 1.0 flight hours for each hour flown on light jet aircraft and 1.2 flight hours for each hour flown on mid-sized jet aircraft, as billed by the operating carrier. The Directors, the CEOs and the Other Officers will be responsible for the payment of the value of any Company flight in excess of their remaining Annual Flight Allowance.

The Directors, the CEOs and the Other Officers may only redeem their Annual Flight Allowance on behalf of themselves, their immediate family and guests.

Regardless of the amount of income, if any, reported in respect of Company flights, each Director, CEO and Other Officer is solely responsible for all taxes in respect of cash and non-cash compensation from the Company, including imputed income.

The Annual Flight Allowance will expire on December 31 of the applicable calendar year. Upon request, any Director, CEO and Other Officer may extend the expiration of any unused, expiring Annual Flight Allowance for an additional twelve months (i.e., to expire on December 31 of the following year), *provided* that no more than 50% of the respective Annual Flight Allowance may be extended (i.e., the Directors may only extend up to 5 flight hours of their unused, expiring Annual Flight Allowance and the CEOs and the Other Officers may only extend up to 10 flight hours of their unused, expiring Annual Flight Allowance).

In periods of limited capacity, any flight for paying customers will take priority over flights organized for Directors', CEOs' or Other Officers' personal travel. At all times, flights pursuant to the Policy must be operated by the Company's in-network operators or at pricing that is consistent with the same. Directors, CEOs and Other Officers must obtain approval from the Head of Fixed Wing Operations for any flights.

For tax purposes, the value of the charter flight will be determined in accordance with the Internal Revenue Service's Standard Industry Fare Level (SIFL) calculation and treated as imputed income (taxable) for the applicable Director, CEO or Other Officer.

*\* \* \* \**

*Effective as of September 1, 2025, this Policy amends and restates the Blade Air Mobility, Inc. Flight Benefit Policy for the Board of Directors and Named Executive Officers* 

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION**

**PURSUANT TO RULE 13a-14 AND 15d-14**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED**

I, Melissa M. Tomkiel, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Strata Critical Medical, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: November 10, 2025 | By: | /s/ Melissa M. Tomkiel |
|  | Name: | Melissa M. Tomkiel |
|  | Title: | Co-Chief Executive Officer (Principal Executive Officer) |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION**

**PURSUANT TO RULE 13a-14 AND 15d-14**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED**

I, William A. Heyburn, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Strata Critical Medical, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: November 10, 2025 | By: | /s/ William A. Heyburn |
|  | Name: | William A. Heyburn |
|  | Title: | Co-Chief Executive Officer and Chief Financial Officer (Principal Executive and Financial Officer) |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350**

**AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Strata Critical Medical, Inc. (the "Company") on Form 10-Q for the period ended September 30, 2025, as filed with the Securities and Exchange Commission (the "Report"), I, Melissa M. Tomkiel, Co-Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as added by §906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. To my knowledge, the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.

---

| | | |
|:---|:---|:---|
| Date: November 10, 2025 | By: | /s/ Melissa M. Tomkiel |
|  | Name: | Melissa M. Tomkiel |
|  | Title: | Co-Chief Executive Officer<br>(Principal Executive Officer) |

---

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350**

**AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Strata Critical Medical, Inc. (the "Company") on Form 10-Q for the period ended September 30, 2025, as filed with the Securities and Exchange Commission (the "Report"), I, William A. Heyburn, Co-Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as added by §906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. To my knowledge, the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.

---

| | | |
|:---|:---|:---|
| Date: November 10, 2025 | By: | /s/ William A. Heyburn |
|  | Name: | William A. Heyburn |
|  | Title: | Co-Chief Executive Officer and Chief Financial Officer<br>(Principal Executive and Financial Officer) |

---

<br>